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IV. ABSTRACT  
 
Stroke incidence is increasing due to the rapidly aging population in developed 
countries. Whereas untreated acute middle cerebral artery occlusion (MCAO) causes 
death in 20% of patients and long-term disability in more than 70% of patients, acute 
stroke therapy with rapid vessel recanalization significantly reduces mortality without 
influencing functional recovery beyond the acute stroke phase. This lack of functional 
recovery suggests a need for innovative therapies that can restore function after 
stroke. 
 
The purpose of these studies was to examine the effects of delayed 
administration of the growth factors erythropoietin (Epo) and vascular endogenous 
growth factor (VEGF) on functional neurological recovery and pyramidal tract 
plasticity in mice.  
 
The first study investigated how subacute delivery of Epo, starting at 3 days 
after stroke onset and continuing for 30 days (1 I.U. /day or 10 I.U. /day; via mini 
osmotic pump), influenced neuronal survival, axonal sprouting and neurological 
function recovery in C57Bl6/j mice submitted to 30-min MCAO. 
 
Epo administered in a 10 I.U. /day dose, in contrast to the 1 I.U. /day 
administration, showed a significant increase in neuronal survival and CD31 + newly-
formed capillaries. This vascular growth enabled further neuroregeneration 
processes. Functional behavioral tests showed a significant improvement of motor 
coordination (RotaRod test) and grip strength (Grips strength test) among mice with 
10 I.U. /day Epo administration, with no improvement for the low dose group.  
 
To investigate the neurological changes underlying these results, two 
anterograde tract tracers (dextrane amines) were injected in the motor cortex 
ipsilateral and contralateral to the ischemic lesion, in mice treated with the higher Epo 
dose. Histological evaluation of the tracers, both at the level of rubral and facial 
nucleus, showed that functional recovery in these animals was due to an increase of 
contralateral projections, accompanied by a compensatory decrease of ipsilateral 
projections. 
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In the second study, VEGF was investigated due to its dual actions on vessels 
and neurons, which have potential for promoting long distance axonal plasticity in the 
ischemic brain. 
 
Mice were submitted to 30 minutes MCAO, followed by the intraventricular 
delivery of normal saline or VEGF (0.004 or 0.02 µg/day) starting 3 days post-
ischemia. The outcome parameters were functional neurological recovery, long 
distance axonal plasticity by anterograde tract tracing and cellular and molecular 
responses examined by histochemistry, RT-PCR and Western blots. 
 
VEGF promoted neurological recovery when administered at the higher 
dosage, by stimulating long distance axonal plasticity in the contralesional but not 
ipsilesional pyramidal tract system. This observation was accompanied by 
deactivation of matrix metalloproteinase-9 (MMP9) in the ipsilesional brain tissue and 
downregulation of axonal growth inhibitors and guidance molecules in the 
contralesional brain tissue. 
 
The results support the concept that brain plasticity is consistent with 
coordinated axonal growth responses both ipsilateral and contralateral to the site of 
stroke. Considering that Epo is well tolerated in humans, clinical studies are now 
conceivable in which Epo is applied in patients in the post-acute stroke phase. 
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1. INTRODUCTION 
 
1.1. Pathophysiology of acute ischemic injury 
 
Stroke is a neurovascular pathology characterized by a sudden or gradually 
progressing obstruction of a large brain artery with induction of a core of necrosis. 
Currently, stroke affects more than 2 million people in the United States, and is the 
third leading cause of death and the leading cause of disability (Rosamond et al., 
2007). 
 
From a pathophysiological point of view, stroke can be divided into two 
categories: ischemic and haemorrhagic. Due to the prevalence of ischaemic stroke in 
clinical practice, the focus of preclinical and clinical studies was positioned on 
ischemic stroke. Thromboembolic events cause blood restriction in a specific brain 
region, leading to an ischemic lesion. The impact of the ischemic lesion on functional 
outcome is mainly shaped by the collateral flow of the region, the degree of vessel 
occlusion (complete versus incomplete) (Saver, 2008), duration of the occlusion 
(transient versus permanent), location (brain regions vary in susceptibility to 
ischemia; Hashimoto et al., 2008) and co-morbidities (arterial hypertension, diabetes, 
atherosclerosis; Hossmann, 2006). These factors play an important role in the 
transition from reversible to irreversible injury and represent the main target in acute 
stroke treatment strategies. 
 
1.1.1. Anatomic considerations of blood flow regulation and 
collateralization 
 
In comparison with other organs, the central nervous system (CNS) has a 
redundancy of arterial supply (Hossmann, 2006). The four extracranial arteries (the 
paired carotids and the vertebral arteries) are inter-connected intracranially by the 
main six collaterals (right and left anterior, middle and posterior cerebral arteries) 
16 
 
forming two rescuing systems at the level of the circle of Willis (see Figure 1) and the 
leptomeningeal anastomoses of Heubner (Hossmann, 2006). 
The circle of Willis provides low-resistance connections between the origins of 
the six arteries, offering a compensation mechanism in the case of extracranial 
obstruction of the carotid and/ or vertebral arteries (Doyle et al., 2008). The circle of 
Willis provides a rescue mechanism against global ischemic processes in the central 
eloquent brain regions, also providing collateral flow under conditions of focal 
cerebral ischemia   (Hossmann, 2006) (Figure 1). 
 
 
 
Figure 1. Anatomy of cerebral arteries: the main six cerebral arteries and their 
interconnections within the circle of Willis. (Figure copied from 
http://neuro4students.wordpress.com/pathophysiology) 
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The degree and the suddenness of vascular occlusion play an important role 
in the process of collateralisation. In case of an embolic complete vascular occlusion, 
the already anatomically present anastomotic devices may not resist the increased 
pressure from the main supplying artery and may fail to produce a functional 
collateralisation (Simons, 2005). On the opposite, a partial occlusion over time, for 
example due to atherosclerosis processes in the vessels, will allow the anastomotic 
vessels to undergo remodelling of the vascular wall by means of arteriogenesis, 
which will allow them to bypass the normal routes in case of critical occlusion of the 
main artery (Busch et al., 2003). 
 
In addition to the anatomical back-up represented by collaterals, the human 
brain possesses another important mechanism that determines the size of ischemic 
injury: the autoregulatory response. In case of reduced blood pressure, the brain 
redistributes blood supply by autoregulatory dilatation of the resistance vessels and 
dilatation triggered by metabolic acidosis surrounding the necrotic core in case of 
ischaemia. Due to autoregulation, blood flows through the dilated vessels passively, 
representing the first rescue mechanism after a vessel occlusion (Dirnagl and 
Pusinelli, 1990). 
 
1.1.2. The concept of ischemic core and penumbra  
 
The human brain requires 20% of total oxygen consumption, used mainly for 
the generation of adenosine triphosphate (ATP), which is necessary for the Na+/K+ 
ATPase pump involved in restoration of ionic gradients (Edvison and Krause, 2002). 
In case of an energy failure, the neuronal membrane cannot repolarize and leads to 
release of the excitatory neurotransmitter glutamate along its concentration gradient 
from the pre- towards postsynaptic membranes (Schubert and Piasecki, 2001). This 
excess glutamate in the extracellular space leads to activation of N-methyl-D-
aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors, stimulating further membrane depolarisation, with an increase in 
intracellular calcium and resulting activation of calcium dependent proteases, lipases 
and DNases, a process called excitotoxicity (Stout et al., 1998; Olney, 1969).  
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These metabolic changes are produced in the core of ischemia, where the 
cerebral blood flow (CBF) is most severely compromised, and then spreads in a 
radial manner to the surrounding tissue. The ischemic core is surrounded by a rim of 
tissue with impaired electrical activity but preserved cellular metabolism and viability, 
called the penumbra (Astrup et al. 1977; Astrup et al, 1981; Hossmann, 1993, 1994). 
Whereas the ischemic core evolves rapidly, and is characterised by necrotic debris, 
the penumbra region has a moderate reduction of CBF, providing a rescue potential 
which depends on the speed of reperfusion of this tissue after ischemia (Baron et al, 
1995; Wise et al, 1983) (Figure 2). 
 
 
 
Figure 2. Ischemic penumbra and biochemical events in radial sprouting from the 
core (figure copied from Dirnagl, et al., 1999) 
 
Based on the dynamics of the penumbra, a therapeutic time window was 
defined for treating acute ischemic stroke. Although the acute delivery of recombinant 
tissue-plasminogen activator (rt-PA) in the first 4.5 hours after stroke correlated in 
clinical studies with a reduced evolution of stroke disease (Hacke W. et al., 2008), 
other neuroprotective treatments failed repetitively in clinical studies. Whereas 
chemical thrombolysis with rt-PA may induce intracerebral haemorrhage after stroke, 
mechanical thrombolysis is proven to increase the therapeutic window and to reduce 
functional disabilities, and is currently the gold standard for acute stroke therapy 
(Gralla et al., 2012; Gralla et al., 2006). The reperfusion of the ischemic tissue in this 
therapeutic window aims to save the penumbra and minimize ischemic damage, and 
to prevent vasogenic edema and haemorrhagic complications after revascularization.  
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1.1.3. Progression of ischemic injury 
 
Neuroprotection therapy after stroke failed in the translation phase, so a better 
understanding of the mechanisms leading to the progression of injury is urgently 
needed. A series of molecular events characterize the cascade of ischemic injury: 
excitotoxicity, oxidative and nitrative stress, dysfunction of endoplasmatic reticulum 
and mitochondrial disturbances (Doyle et al., 2008).  
 
The immediate release of excitatory neurotransmitters after stroke and 
simultaneous activation of their receptors results in an increased calcium 
concentration inside the cell, leading to mitochondrial calcium overload and activation 
of calcium-dependent catabolic enzymes (Choi, 1994). The main neurotransmitter 
involved in this process is glutamate (Schubert and Piasecki, 2001; Stout et al., 
1998). Glutamate activates metabolic processes by stimulation of Inositoltriphosphate 
(IP3) dependent transduction pathways, modifying their responses in the brain 
(Kiessling and Gass, 1994) and thereby inducing excitotoxic injury (see Figure 3). 
 
Because neurons have low levels of endogenous antioxidants, they are 
extremely vulnerable to reactive oxygen species. The activity of nitric oxide synthase 
(NOS) is stimulated under hypoxic conditions, leading to an increase in nitric oxide 
(NO) and peroxynitrate concentration (Kunz et al, 2007). Oxidative stress correlates 
with over-activation of poly (ADP-ribose) polymerase-1 (PARP-1), a DNA repair 
enzyme, which catalyses the transformation of β-nicotinamide adenine dinucleotide 
(NAD+) into nicotinamide (NA) and long polymers of poly (ADP-ribose) (PARP) 
(Sairanen et al., 2009). Over-activation of intracellular PARP-1 leads to a depletion of 
NAD+, causing an impairment of NAD+ dependent cellular processes such as 
anaerobic glycolysis and mitochondrial respiration, resulting in ATP starvation and 
neuronal death (Gingsberg, 1997). 
 
The second phase of oxidative stress is observed during the reperfusion-
induced injury phase, and is characterised by activation of matrix metalloproteases 
(MMPs), which affect the integrity and functionality of the blood brain barrier (BBB) 
(Valable et al., 2005). These second phase activities may lead to parenchymal 
haemorrhage and vasogenic brain edema, and may also explain why the therapeutic 
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window of thrombolytic therapy has a time-dependent functional limitation (Crack and 
Taylor, 2005). 
 
The increase of cytosolic calcium activity leads also to increased permeability 
of inner mitochondrial membranes, which leads to formation of MPT (mitochondrial 
permeability transition) pores (Siesjö et al., 1999). This causes swelling of 
mitochondrial matrix, allowing release of pro-apoptotic mitochondrial proteins which 
activate the cysteine protease caspase 3, an important initiator of apoptotic cell death 
(Krajewski et al., 1999) (Figure 3). 
 
 
Figure 3. Excitotoxicity after stroke (figure copied from Duan et al., 2007) 
 
Depending upon the pathophysiological mechanism, stroke leads to two types 
of edema: cytotoxic (caused by cellular swelling) and vasogenic (caused by leakage 
of the BBB) (Hossmann, 1989, 1993). 
 
Alteration of ionic balance in the necrotic core lesion with an increase of the 
intracellular sodium gradient causes intracellular water accumulation by means of 
osmotic gradient dependent forces (Todd, 1986). This leads to a cytotoxic 
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oedematous transformation of the ischemic core, which is later augmented by the 
disruption of the brain-blood barrier (BBB) approximately six hours after ischemia. 
Whereas cytotoxic oedema results from acute changes in ionic balance after stroke, 
the vasogenic edema reaches a peak approximately two days after stroke (Walz et 
al., 2002). The clinical relevance of brain oedema is exemplified by the so-called 
malignant infarct, which causes swelling of the infarcted region over the anatomical 
borders of the skull, and may result in life-endangering transtentorial herniation and 
midbrain compression if a decompressive craniectomy is not immediately performed 
(Hacke et al, 1996; Bardutzky and Schwab, 2007). 
 
The complex pro-inflammatory reaction after stroke was shown to cause an 
increase in the structural ischemic damage and it is a target for neuroprotective 
treatments in stroke (Dirnagl, et al., 1999). The inflammatory processes in the brain 
differ from other tissues due to the brain’s evolutionary privilege in having an 
anatomical and physiological barrier (the BBB) and an immunological barrier 
(reduced expression of major histocompatibility complex class-I and class-II antigens 
on specific cells in the CNS) (Schwartz, et al., 1999). These particular characteristics 
are responsible for the dual role of inflammation during pathophysiologic processes in 
the brain such as in ischemic stroke.  
 
Different inflammatory mechanisms were shown to negatively influence the 
ischemic damage in the brain, producing microvascular obstruction, increase of 
acidosis, elimination of toxins, production of reactive oxygen species (ROS) (del 
Zoppo et al., 1991; Dirnagl et al., 1999). These processes induce BBB disruption, 
leading to release of histamine and proteases with activation of inflammatory cells in 
the perivascular space, which create a proinflammatory milieu in the brain 
parenchyma due to cytokine production (tumour necrosis factor [TNF], Il-1β) 
(Iadecola and Anrather, 2011). 
 
After stroke, programmed cell death occurs in the ischemic penumbra and is 
triggered by oxygen reactive free nitric radicals, death receptor activation, DNA 
damage and protease activation. There are two important pathways for induction of 
apoptotic death: the intrinsic and the extrinsic pathways (Hossmann, 1989, 1993). 
The apoptotic cascade starts with the intracellular release of cytochrome c from the 
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outer mitochondrial membrane in response to ionic imbalance and mitochondrial 
swelling. After release from the outer membrane, cytochrome c binds to ATP, 
procaspase 9 and apoptotic protease activating factor 1 (Apaf1), creating an 
apoptosome (Krajewski et al., 1999). The apoptosome is responsible for DNA 
degradation and p53 activation, leading to an increase of Bax expression which 
further promotes mitochondrial pore formation and mitochondrial swelling (Brad et al., 
2009; Mattson et al., 2000). The extrinsic cascade involves death receptors 
independent of the release of cytochrome c. Death-receptors activate caspase-8 and 
caspase-10, which finally involve caspase 3 and cause DNA degradation (Namura et 
al., 1998). 
 
1.2. Clinical aspects of stroke research 
 
The human brain possesses endogenous rescue mechanisms such as: 1) 
long time arteriogenesis of collateral vessels that enable rapid re-routing of blood flow 
in case of a sudden obstruction (Busch et al, 2003); 2) glial scar formation in the 
close vicinity of the ischemic core with neuroprotection potential (Trandelenburg and 
Dirnagl, 2005); 3) tissue-remodeling by reactivation of ontogenetic repair 
mechanisms (Cramer and Chopp, 2000). Trying to sustain these endogenous 
strategies leads to three therapeutic stroke research strategies: acute chemical or 
mechanical thrombolysis, neuroprotection therapies and neurovascular restorative 
strategies. Because our study focuses on the third aspect, Chapter 1.3 is dedicated 
to the restorative mechanisms and therapeutic strategies after stroke. 
 
1.2.1. Thrombolysis and mechanical recanalization 
 
Intravenous tissue plasminogen activator was proven to be the first successful 
stroke therapy in acute ischaemic stroke, but it successfully recanalizes MCAOs in 
only one-third of cases. Only a very rapid recanalization, achieved within minutes to 
hours before irreversible brain damage develops, has proven to be effective (Cohen, 
2013). Mechanical thrombectomy detaches the intra-arterial thrombus and allows 
rapid revascularisation of the ischemic region, and can be used in a looser time-
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window of up to eight hours after stroke (Fiehler, 2012). However this therapy still 
needs to be proven in prospective clinical trials and the side-effects are not yet fully 
characterised (Lo et al., 2003). 
 
Chemical thrombolysis, either systemic or regional, by endovascular methods 
also proved to be effective in the treatment of acute ischemic stroke. It was reported 
that with increasing delay of the application of thrombolysis therapy, there was a 
decline in the therapeutic effect; the critical period was restricted to 3 to 4.5 hours 
after onset of symptoms (Hacke et al, 2008). Although it was reported that 
thrombolysis decreases mortality (Wardlaw et al, 2003), this treatment is effective in 
a narrow time-window after the onset of stroke (Brown et al, 2003). A new time-
independent therapy is required in order to facilitate treatment for all stroke patients 
irregardless of the health and economic systems in the various countries. 
 
Recent studies report that increasing delay of intravenous thrombolysis 
administration after stroke causes a decline in the therapeutic effect (Brinker et al. 
2003; Vergouwen et al, 2012). In case of mechanical thrombolysis, a recent study 
confirmed that time to treatment is a predictor of outcome, but only when collaterals 
were excluded from the stroke model of the anterior circulation (Galimanis et al., 
2012). Even in studies where it was proven that thrombolysis decreases mortality 
(Wardlaw et al, 2003), this treatment was restricted to patients treated within a 
specific time period after the onset of stroke (Brown et al, 2003). 
 
The concept of “stroke care unit” was developed in order to increase the 
efficiency of stroke treatment, by reducing the time-to-diagnosis and time-to-
treatment window, and led to a significant reduction in mortality and institutionalised 
care in the first 10 years (Indreadavik et al., 1999). Strategies for improving functional 
recovery after stroke have unfortunately not yet been established in clinics, leading to 
permanent functional impairment in the majority of patients.  
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1.2.2. Neuroprotection  
 
Neuroprotection aims at reducing ischemic injury by preventing apoptosis, 
inflammation, metabolic distruptions and neurotransmitter disturbaces in the ischemic 
area. Despite intensive research and promising preclinical results, all the 
neuroprotective drugs failed in the clinical translation phase (Gingsberg, 1997). The 
most important candidates of this group are described breifly below. 
 
Glutamate antagonists were proved to reduce the size of ischemic lesion 
(Iijima et al., 1992; Gill et al., 1992). Reduction of neuronal necrosis after stroke was 
linked to glutamate antagonists, antioxidant substances meant to stop the formation 
of reactive oxygen species (ROS), and substances meant to stop delayed neuronal 
death (e.g., apoptosis). 
 
Aiming to interfere with the development of cytotoxic oedema, aquaporin 
channel inhibitors meant to block intracellular water accumulation were investigated. 
It was shown that aquaporine channel inhibitors reduced ischemic injury (Griesdale 
and Honey, 2004). However, it was later proven that aquaporine channel inhibitors 
merely delayed edema formation (Hossmann, 2006). 
 
Interleukin (IL)1-beta was for a long time considered to be a promising 
neuroprotective target, since administration of interleukin 1-beta receptor antagonist 
(IL-1ra) reduced infarct size (Stroemer and Rothwell, 1998). However the transition of 
these therapies into the clinic failed repeatedly. The SAINT-II (Stroke Acute 
Ischaemic NXY Treatment) study tested the antioxidative agent NXY-059 as 
neuroprotectant in stroke patients. This study did not reveal efficacy in phase III trials 
(Savitz and Fisher, 2007; Savitz, 2007) and had to be interrupted. 
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1.3. Restorative mechanisms in post-acute stroke phase 
 
Stroke remains the leading cause of serious motor disabilities in adults (Bonita 
and Beaglehole, 1994). Hemiparesis initially affects 80-90% of patients, and 45-60% 
of patients still exhibit motor deficits in the post-acute stroke phase (Dobkin, 1996). 
Thus, patient recovery is limited.  
 
Post-ischemic endogenous responses of the CNS correspond to an enhanced 
sensitivity to rehabilitative (Biernaskie et al., 2004) and plasticity-promoting 
(Papadopoulus et al., 2002; Seymour et al., 2005) treatments, opening a time 
window in which ontogenetic brain repair mechanisms may successfully be 
reactivated (Cramer and Chopp, 2000; Buchli and Schwab, 2005; Hermann and 
Chopp, 2012). 
 
The observation of endogenous regeneration potential after stroke, by means 
of neurogenesis (Jin et al., 2001), angiogenesis (Krupinski et al., 1994), functionally 
active stem cells (Gould et al., 1999), axonal sprouting (Reitmeir et al., 2011,2012) 
and synaptogenesis paved the way for post-acute treatments. 
 
1.3.1. Endogeneous neurogenesis 
 
Formation of neuronal stem cells (NSCs) starts in the gastrulation phase and 
continues throughout the embryonal phase by a continuous proliferation in the 
ventricular zone (Clark and Chiu, 2003). Radial glia cells, situated in the 
subventricular zone (SVZ) (Clark and Chiu, 2003), migrate to the primordial dentate 
hilus of the hippocampus, forming the subgranular zone (SGZ) and the dentate gyrus 
(DG) (Pleasure et al, 2000). In the adult brain these NSCs were found to proliferate in 
the SVZ, SGZ and the posterior periventricular (PPv) area (Gage, 2000; Alvarez-
Buylla et al., 2002). This represents an endogenous pool which was shown to be 
activated by focal ischemia (Yan et al., 2006) both in the ipsilesional and in the 
contralesional hemisphere (Zhang et al., 2001 a,b), reaching a peak 1-2 weeks after 
stroke and returning to sham levels by 3-4 weeks (Dempsey et al., 2003, Zhu et al., 
2003).  
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The process of neurogenesis includes three major anatomical steps: 
proliferation, migration and differentiation (Iwai et al., 2002) which are followed by 
functionality steps such as development of electric potential of the newly formed 
neuron and its integration into the cellular matrix environment. 
 
Promotion of neuronal proliferation after stroke was intensively studied using 
different growth factors, and the most promising are Epo and VEGF. Ischemia was 
proven to stimulate the hypoxia-induced factor-1 (HIF-1) as a main player in the 
signal cascade after stroke. The smallest reduction in oxygen partial pressure in the 
brain leads to a strong activation of HIF-1. Both VEGF and Epo are responsible for 
the down-stream effects of HIF-1 (Pugh and Ratcliffe, 2003). Epo knock-out mice 
show deficiencies in post-ischemic neurogenesis (Tsai et al., 2006) and VEGF 
promotes neurogenesis both in vitro and in vivo (Wang et al., 2007). 
 
Endogenous NSCs in the normal brain follow the route of rostral migratory 
stream (RMS) towards the olfactory bulb, whereas in the ischemic preconditioned 
brain, the NSCs migrate towards the injured areas in the brain (Thored et al., 2006, 
Arvidsson et al, 2009). Important mediators in this process of migration and 
maturation are the MMPs, especially MMP9, which is upregulated in the infarcted 
cortex of rats 7-14 days after infarct. MMP9 colocalizes with Doublecortin (DCX) and 
Bromo-deoxy-uridine (BrdU) positive cells migrating from the SVZ (Zhao et al., 2006). 
Wang et al. reported that conditioned medium from Epo-treated epithelial cell cultures 
significantly increased the neural progenitor migration which was impaired by MMP 
inhibitor (Wang et al., 2006). 
 
Even when there is evidence for migration and maturation of NSCs to the 
ischemic lesion, the functionality of these neurons, their long-time survival, and their 
integration in the peri-neural and angiogenic milieu is still controversial. Such survival 
and integration is necessary in order to support beneficial recovery after stroke. 
VEGF and Epo are thought to be promising candidates to facilitate this functional 
integration. Up to now they have been proven to be stimulating factors for 
neurogenesis, angiogenesis, migration and maturation, so the only missing puzzle 
piece is their potential role in axonal sprouting with integration in peri-neural matrix.  
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1.3.2. Angiogenesis and neurovascular remodelling after stroke 
 
A complex intercellular orchestration is needed to create permissive conditions 
for functionally relevant axonal and dendritic sprouting after ischemic injury in the 
brain. The vascular and nervous systems share multiple similarities in their 
development, both of them using long-distance projections to reach their target, 
being guided by gradients of growth factors (Hermann and Zechariah, 2009). The 
parallel tracking of blood vessels and nerves is especially obvious in peripheral 
nervous tissues. In the CNS, neurogenesis takes place in the embryologic vascular 
niches where endothelial cells (ECs) proliferate. Thus, both systems have to be taken 
into consideration as a homeostatic unit, especially in neuropathological events of the 
brain such as stroke (Hermann and Zechariah, 2009). 
 
The formation of new vessels alone has less impact upon neural regeneration 
after stroke, unless functionality of the neurons is maintained. There are two 
important aspects that should be considered when discussing functional integrity of 
newly formed vessels: first they should lead to an increase in the cerebral blood flow 
proportional with the increase in vessel density, and second they should integrate in 
an incipient neurovascular niche by forming new physiologically active units in the 
process of regeneration after stroke. 
 
Both neurogenesis and angiogenesis seem to take place in the same time-
window, starting about 48 hours after the stroke occurs (Seylaz et al, 1999; Marti et 
al., 2002). This vessel formation is probably too late to influence injury development 
in stroke (Hermann and Zechariah, 2009), supporting the idea that vascular 
remodeling is more involved in restorative and plasticity processes. 
 
Pharmacological interference with angiogenesis and neurogenesis may 
disrupt these systems, thereby hindering stroke recovery. Early post-ischemic 
administration of VEGF to ischemic rats increased BBB leakage and infarction 
volume in the ischemic brain (Zhang et al., 2000), whereas late-administration (48 
hours) enhanced angiogenesis, decreased BBB leakage and improved stroke 
recovery (Chae et al., 2000). 
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1.3.3. Axonal plasticity  
 
Efforts from the last decade showed that not only that the brain itself has an 
intrinsic capacity to regenerate after stroke, but also that extrinsic factors can be used 
to successfully stimulate regeneration. Recent data shows that the adult brain has 
intrinsic reorganisation and repair potential after stroke (Cramer and Chopp, 2000). 
This plasticity potential is represented at the anatomical level by: recruitment of 
axons that sustain the same function as the destroyed ones but have a different 
anatomical form, synaptogenesis, dendritic arborisation, fortification of functional 
silent synaptic connections, and long distance fiber sprouting (Carmichael et al, 2001, 
2003). These events take place in the first days and weeks after the ischemic lesion, 
and their susceptibility to external therapeutic factors is negatively correlated with 
time. 
 
An understanding of the molecular, cellular, anatomical and temporal self-
repair capacity of the brain after stroke is necessary in order to develop cell- and 
pharmacologic-based therapies. In order to understand how we can stimulate 
plasticity after stroke, plasticity during ontogeny is an important consideration. 
 
1.3.3.1. Corticospinal system: evolution and ontogenetic development 
 
Whereas non-mammals possess precocious motor skills immediately after 
birth, many mammals are born with only the simple motor behaviours necessary for 
survival, such as breathing and feeding-related behaviours (Muir, 2000). Human 
motor development is completed within the first few years after birth. Whereas the 
brainstem motor systems are well developed at birth, the corticospinal system is not 
(Kudo et al., 1993). The development and maturation of corticospinal connections in 
humans take place over years, forming the principal motor system for voluntary limb 
control (Eyre, 2003). 
 
Human corticospinal axons reach the lowest cervical spinal cord by 24 weeks 
postconceptional age (PCA) (Stanfield, 1992). At about 40 weeks PCA the 
expression of neurofilaments begins and myelination of corticospinal axons is still 
ongoing (Stanfield, 1992). Nathan et al. demonstrated that 8 to 15% of the 
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corticospinal tract is represented by uncrossed axons (Nathan et al., 1996). These 
ipsilateral corticospinal tract fibers originate from the same cortical areas as the 
contralateral fibers and present a similar pattern of spinal innervation as the 
contralateral projection (Nathan et al, 1996). 
 
1.3.3.2. Plasticity of corticospinal tract after stroke 
 
Stroke is the leading cause of chronic disability, as many patients survive the 
acute event and undergo a first phase of innate spontaneous recovery which is 
usually insufficient for a complete recovery. Attempts to augment innate functional 
recovery after stroke are now in a focus of pre-clinical and clinical studies. 
 
An exciting pathophysiologic aspect in stroke recovery is the opening of a 
time-limited neuroplasticity window due to reactivation of ontogenic mechanisms 
similar to ones described in the developing nervous system (Cramer and Chopp, 
2000; Carmichael and Li, 2006). This attempt towards self-reorganisation of the CNS 
after stroke corresponds with an enhanced receptivity of the ischemic brain towards 
neuroregenerative pharmacologic therapy (Biernaskie et al., 2004; Brown et al., 
2009; Carmichael et al., 2006). Extensive studies in non-human species provided 
deep insights into the understanding of the complex interactions taking place during 
brain remodelling after ischemic injury.  
 
A series of temporo-spatial events have been suggested as important players 
in this reorganisation process. The peri-infarct region undergoes molecular changes 
with fibre sprouting of surviving neurons (Li and Chopp, 1999), synaptogenesis (Wall 
and Egger, 1971), dendritic arborisation (Jones and Schallert, 1992) and sprouting 
over long distances by unmasking of latent horizontal connections (Sanes and 
Donoghue, 2000). This long distance fiber sprouting implicates the non-ischemic 
hemisphere and other distal structures like the red nucleus and basilar pontine nuclei. 
These events are initiated after the “hyperacute and acute” post-stroke phase (up to 
72 h after onset), unfold in the subacute recovery phase, and reach  optimal 
efficiency in the first 2 weeks after parenchymal injury (Kreisel et al., 2006). This 
expansive temporospatial pro-plasticity conditioning of the brain towards more 
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responsiveness to brain remodelling opens new frontiers for delayed and chronic 
therapeutic neurorehabilitation possibilities after stroke. 
 
Latent interneuronal network nodes connect the lesional or perilesional area 
with other distant secondary, associative or contralateral cortical areas in the brain, 
and are reactivated after stroke. Their degree of excitation is conditioned by the 
primary localisation of the stroke and by its size (Kreisel et al., 2006) (Figure 4). A 
subcortical stroke was shown to disrupt cortical inhibition in the unaffected 
hemisphere (Shimizu et al., 2002). Recruitment of these increased activation areas 
from the contralesional hemisphere correlated with a better recovery after stroke 
(Feeney and Baron, 1986). This remapping potential was shown to be greater in 
models of relatively small strokes that resemble the size of a survivable human stoke 
(Cramer and Crafton, 2006). The present study is based on 30 minutes MCAO as a 
stroke model, which produces a localised, reproducible and focal subcortical infarct. 
 
The role of the contralateral hemisphere in functional recovery after stroke 
remains controversial. A series of events observed in the intact hemisphere after 
stroke, such as increased blood flow (Silvestrini et al., 1998), metabolism (Marshall et 
al., 2000), excitability (Iglesias et al., 1996), inflammatory markers (Haring et al., 
1996), and sprouting of dendrites and synapses, also have a delayed onset in the 
subacute stroke phase, leading to the speculation that these events may provide the 
anatomical background for the plasticity-promoting phase initiated in the 
contralesional hemisphere (Jones and Schallert , 1992). These events correlated with 
improved functional outcome after stroke in non-human animal models, in clinical 
practice the degree of contralesional activation was observed to be more intense in 
patients with worse outcome after stroke (Calautti and Baron, 2003; Ward, 2011). 
The goal of the present study is to clarify the role and nature of interhemispheric 
interactions after subcortical stroke injury, and to examine their impact on post-stroke 
recovery. 
 
Preclinical and clinical studies on unilateral ischemic brain damage have 
demonstrated that reorganization of the corticospinal tract in the intact hemisphere 
may increase functional outcome after stroke. Ischemia of the corticospinal tract 
leads to degeneration (Eyre, 2003). This leads to postsynaptic inactivation of spinal 
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cord motoneurons and subsequent postsynaptic degeneration, unless fibers of other 
subcortical nuclei take over the distal corticospinal function. In a non-human animal 
model, the rubrospinal tract was shown to take over the function of the corticospinal 
tract projections, thus promoting functional recovery after stroke (Papadopoulos et 
al., 2001). In humans the role of the rubrospinal tract is not well defined.  
 
 
Figure 4. Axonal sprouting after stroke (figure copied from Murphy and Corbett, 
2009). This figure explains the recovery of sensorimotor function after stroke. In case of 
small and medium stroke lesions the nearby tissue with similar sensorimotor function will 
contribute to the recovery process through a strengthening of difusse synaptic connections or 
by creation of new structural connections under the guidance of synaptic learning rules. In 
case of large ischemic lesions the recovery will be sustained by circuits coming from the 
contralateral hemisphere which are interconnected at subcortical level. The primary motor 
cortex (M1) and hindlimb (sHL), forelimb (sFL) and secondary somatosensory cortex (S2) 
are indicated. 
 
Kreisel et al. (2006) proposed a timeline of recovery processes after stroke, 
differentiating between 5 distinct stages: (1) hyperacute phase from the stroke event 
up to 6 hours after; (2) acute phase lasting up to the fourth day after stroke, 
characterised by secondary events; (3) subacute phase from the second day up to 2-
3 weeks, characterised by neurofunctional plasticity; (4) consolidation period lasting 
up to several months, characterised by neurofunctional alteration; (5) chronic phase 
characterised by the tendency of the events to become static. 
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1.3.4. Extracellular matrix as a trigger for axonal plasticity 
 
The extracellular matrix (ECM) consists of: 1) Glucoseamineglycans (GAGs) 
which may be found either bound with proteins (proteoglycans) or unbound as 
hyaluronan; 2) fibrous proteins (e.g. collagens and elastin); 3) adhesive glycoproteins 
(e.g. fibronectin, laminin and tenascin) and 4) a wide variety of growth factors bound 
(inactive) or unbound (active) to matrix. 
 
Besides its structural role, the ECM controls functional interactions between 
cells in different processes such as development, cell survival and tissue 
homeostasis (Oohira et al., 2000). After stroke, the composition of the ECM is altered 
(Charmichael, 2003). Among the regulated molecules, chondroitin sulphate 
proteoglycans (CSPGs), such as aggregan, versican and phosphacan, have been 
reported to be involved in stroke recovery processes (Charmichael, 2003).  
 
1.3.5. Clinical evidence of corticospinal tract plasticity after stroke 
 
Evidence from positron emission tomography (PET), functional magnetic 
resonance imaging (fMRI), transcranial magnetic stimulation (TMS) and 
magnetoencephalography (MEG) studies also supported the relevance of 
contralesional brain plasticity for human stroke recovery (Gerloff et al., 2006; van der 
Zijden et al., 2008; Ding et al., 2008). However, implications of contralesional 
activation were difficult to interpret as activation patterns in humans are strongly 
influenced by the severity and inhomogeneity of strokes. Whether the promotion of 
functional neurological recovery with growth factors influences contralesional 
reorganization processes was until not described.  
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1.4. Role of growth factors in stroke recovery 
 
1.4.1. Erythropoietin (Epo) 
 
The discovery of erythropoietin (Epo) and its receptor in neurons and 
astrocytes (Bernaudin et al., 2000) represented the beginning of a decade of follow-
up studies which established Epo as a neuroprotective factor after stroke. Epo 
inhibits apoptosis in the tissue adjacent to the lesion (Tan et al., 1992) and modulates 
nitric oxide synthesis (Siren et al., 2001) and neurotransmitter release after stroke 
(Minnerup et al., 2009). 
 
A small clinical study classified Epo as being “both safe and beneficial” for 
acute stroke (Ehrenreich et al, 2002). Based on these results a multicentre clinical 
trial was conducted with 522 patients in whom Epo (40,000 I.U./administration) was 
infused intravenously at 3 timepoints (6, 24 and 48 h) after acute ischemic stroke 
both in patients with and without concomitant rtPA administration. Surprisingly, the 
study showed an increased mortality in patients treated with both Epo and rtPA, 
whereas Epo alone showed a neuroprotective effect (Ehrenreich et al., 2009). Further 
preclinical investigations showed that Epo administered together with rtPA after 
stroke increases brain edema, thereby increasing mortality after stroke (Zechariah et 
al, 2010). This is why a thorough evaluation of experimental conditions is necessary, 
as improper testing puts not only patients at risk, but also endangers future studies 
aimed at investigating the therapeutic potential of Epo in stroke patients. Because of 
this interaction between therapy and rtPA in the first hours after stroke, a delayed 
administration may reduce this interaction potential and thus enable the innate 
regeneration capacity of the brain. 
 
The post-stroke potential of Epo must still be analysed and understood at the 
basic research level. Epo was shown to have neuroregenerative potential in a rodent 
model of Parkinson’s disease, where it increased fiber outgrowth in the ventral 
mesencephalon (McLeod et al., 2006), by enhancing axonal sprouting in a model of 
optic nerve transection (King et al., 2007; Kilic et al., 2005b) and by enhancing white 
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matter reorganisation in rat focal ischemia (Li et al., 2009). The neuroregeneration 
potential of Epo after stroke, and particularly its effects on axonal plasticity and 
interhemispheric remodelling, have not been fully explored (Bernaudin et al., 1999). 
Therefore, the present study explored the effects of Epo after a MCA occlusion 
(stroke model) in mice. 
 
The inflammatory response after stroke is receiving increasing attention in the 
field of brain tissue remodelling and reorganisation. Experimentally and clinically, 
stroke is followed by an acute and a chronic inflammatory response. Microglia cells 
seem to have a dual role in the orchestration of cellular recovery after stroke. 
Whereas microglia are detrimental for neurogenesis after stroke during the acute 
phase (mainly driven by Il-6 and TNFά synthesis) (Iosif et al., 2006; Koo and Duman, 
2008), a chronic activation pattern of these cells was correlated both in vivo (Bonde 
et al., 2006) and in vitro (Walton et al., 2006) with long-term survival of newly formed 
neurons after stroke. Another important factor that mediates the cause-effect 
interrelationship between inflammation and regeneration is the activation of 
astrocytes with the formation of glial scar, a cellular-biochemical wall that inhibits 
axonal regeneration after stroke.  
 
The present study evaluated the effect of delayed Epo administration upon 
local and distal tissue reorganisation, acute and chronic inflammation and functional 
recovery after stroke, presenting for the first time a complete picture of the temporo-
spatial processes that culminate with an improved recovery post-stroke. 
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1.4.2. Vascular endogenous growth factor (VEGF) 
 
Subsequent to a stroke, the brain tissue undergoes profound remodeling 
processes involving finely tuned cell-cell (Zhang and Chopp, 2009) and cell-
extracellular matrix (ECM) (Zhao et al., 2006) interactions, aimed at the reconstitution 
of a functional neurovascular system. These events are sustained by ontogenic 
protein expression programs which are reactivated after stroke (Cramer and Chopp, 
2000). These programs stimulate de novo expression of ECM proteins and their 
proteases (MMPs) in the peri-lesional tissue (Zhao et al., 2006). Matrix molecules 
orchestrate inter- and intracellular pathways, facilitating interactions of growth factors 
with the cellular surface (Yong, 2005). 
 
VEGF is an endogenous growth factor which is activated in hypoxic conditions 
in the brain via activation of HIF-1α expression (Forsythe et al., 1996), which then 
stimulates the transcription of VEGF, VEGF receptors (flt-1 and neuropilin-1), and 
angiopoietin (Pugh and Ratcliffe, 2003). Because two additional anatomical 
disruptions occur in the acute phase after stroke, loss of vascular integrity and cell 
matrix degradation (Hermann and Zechariah, 2009), VEGF`s activation is 
potentiated. These two processes facilitate the activation of growth factors, their 
receptors and their guidance molecules, which are incorporated in the cellular matrix 
in a functionless state under normal conditions. Endogenous VEGF is activated by 
cellular matrix degradation, which activates angiogenesis and thereby induces 
endothelial cell proliferation and migration after stroke (Carmeliet, 2003). 
 
The VEGF family comprises 5 related genes: VEGF-A, -B, -C, -D and PIGF 
(placenta induced growth factor). VEGF-A is a vascular permeability factor and has 
several isoforms (VEGF-A204, -A189, -A165, -A145, -A121) which have different amino 
acid length and capacity of binding to heparin sulfates. VEGF-A165 binds heparan 
sulfate to some extent, which reduces its diffusibility but at the same time increases 
its ability to stimulate VEGF receptors (Simons, 2005). 
 
Recent data in non-human primates subjected to circumscribed infarcts of the 
motor cortex showed that in addition to associating with neurons throughout the 
lesioned hemisphere, VEGF can also be found in injury-remote neurons of the 
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contralateral motor cortex (Stowe et al., 2007). The VEGF receptor VEGFR2 is de 
novo expressed on motor cortical neurons remote from the lesion site (Stowe et al., 
2008). This observation raises questions about VEGF's role in the reorganization of 
ischemic brain tissue. Besides VEGF and its receptors, MMP9 is also upregulated in 
cerebral cortex surrounding a stroke lesion for up to 14 days (Zhao et al., 2006). 
Colocalization of MMP9 with markers of neurovascular remodeling suggested that 
MMP9-induced matrix degradation contributes to brain plasticity (Zhao et al., 2006). 
Recruitment of remote brain areas has been shown to contribute to neurological 
recovery after stroke in rodents (Papadopoulos et al., 2002; Wiessner et al., 2003; 
Reitmeir et al. 2011) and humans (Gerloff et al., 2006; van der Zijden et al., 2008). By 
means of anterograde tract-tracing techniques, pyramidal tract plasticity can be 
analyzed in rats (Papadopoulos et al., 2002; Wiessner et al., 2003) and mice 
(Reitmeir et al., 2011). 
 
In view of the unique activities of VEGF in stimulating the survival and 
proliferation of endothelial cells and neurons, we sought to determine whether VEGF 
influences long distance axonal plasticity in the ischemic brain and, secondly, how 
angiogenesis and axonal plasticity are linked. For this purpose, a comprehensive 
analysis was performed to characterize the effects of post-acute VEGF delivery on 
neurological recovery, perilesional vascular remodeling, and pyramidal tract plasticity 
ipsilateral and contralateral to a stroke.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
2. AIMS OF THE STUDY 
 
2.1. Effect of delayed Epo administration on axonal plasticity 
modulation and functional recovery after stroke 
 
Promising results from pre-clinical studies, in which Epo was found to be 
neuroprotective after ischemic brain injury, failed to be translated into clinical efficacy 
in the German Multicenter EPO Stroke Trial (Ehrenreich et al., 2009). The main 
reason for clinical failure was an unfavourable interaction between Epo and rt-PA, 
which resulted in an increase in death, intracerebral haemorrhage, brain edema and 
thromboembolic events (Ehrenreich et al., 2009; Zechariah et al., 2010). In view of 
these results we wondered if a delayed Epo administration 3 days after stroke would 
influence functional stroke recovery and axonal sprouting. 
 
The inflammatory reactions in the acute phase after stroke are responsible for 
the boost of neurogenesis that occurs in the post-acute phase (Zhang et al., 2004; 
Jin et al., 2001). The role of chronic inflammation after stroke and its impact upon 
regeneration was until now poorly examined. One of the purposes of this study was 
to characterise in the post-acute phase how inflammatory processes are associated 
with stroke recovery 
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2.2. Effect of delayed VEGF administration on axonal plasticity 
modulation and functional recovery after stroke 
 
The mutual interactions between vessels and neurons are a major challenge 
in neurobiology as they unravel basic principles of brain structure and function. 
During development, angiogenesis and neuronal sprouting are closely linked. It is 
widely assumed that new vessel formation and axonal sprouting mutually promote 
each other, forming a functional neurovascular unit driving reorganization processes 
in the injured brain (Hermann and Chopp, 2012). However, experimental evidence for 
this concept is scarce (Hermann and Zechariah, 2009). The relationship between 
angiogenesis and axonal plasticity has so far not yet been addressed in experimental 
studies.  
 
Aiming to explain how the plasticity is coordinated between the two 
hemispheres after stroke, we examined effects of VEGF on pyramidal tract plasticity 
and extracellular matrix remodelling. By measuring the expression of different 
proteoglycans in different regions of the brain, we characterised molecular signals 
controlling plasticity responses in the ischemic brain. 
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3. MATERIALS AND METHODS 
 
3.1. Animal groups 
 
Experiments were performed in accordance with National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals with local government 
approval (Kantonales Veterinäramt Zürich, ZH169/2005; Bezirksregierung 
Düsseldorf, TSG966/08). Male C57Bl6/j mice (8-10 weeks; 23-25 g) were subjected 
to 30 min of left-sided middle cerebral artery occlusion (MCAO) (Kilic et al., 2005a, 
2006, 2008). At 72 hours post-ischemia, mice received implantations of miniosmotic 
pumps into the left-sided lateral ventricle that were filled with 0.9% NaCl (vehicle) or 
Epo (1 or 10 I.U. / day diluted in 0.9% NaCl) or VEGF (0.004 µg or 0.02 µg / day 
diluted in 0.9% NaCl) and were left in place during the subsequent four weeks (Fig. 5 
and Fig. 6).  
 
In addition to the mice undergoing MCAO, sham-operated mice were also 
operated, in which vehicle filled pumps were implanted as specified. One set of mice 
was used for studies on functional neurological recovery and for analysis of axonal 
plasticity (n = 10 animals per group). For that purpose, mice received anterograde 
tract tracer injections (see below) in both frontal motor cortices at 42 days after the 
stroke was induced. Ten days later, these animals were sacrificed. 
 
Additional male C57Bl6/j mice were also subjected to 30 min MCAO using the 
same protocol, followed by implantation of intraventricular pumps filled with vehicle or 
Epo (10 I.U. / day in 0.9% NaCl) (Fig. 5) or VEGF (0.004 µg or 0.02 µg / day diluted 
in 0.9% NaCl) (Fig. 6) three days later. These animals were sacrificed at 3, 14 and 30 
days (used for reverse transcriptase-polymerase chain reaction [RT-PCR] studies) or 
at 14, 30 or 52 days (used for conventional immunohistochemical studies) after the 
stroke (n = 4 animals per group, survival time and series). For RT-PCR studies, 
additional sham-operated mice (n = 4) and control mice subjected to 30 min MCAO 
without pump implantation (n = 4) were also operated. The latter sham-operated and 
untreated mice were sacrificed at 3 days post-surgery. 
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Figure 5. Experimental procedures and animal groups in Epo experiment. 
 
Mice subjected to MCAO that were treated with Epo or vehicle from 3 – 30 days post 
ischemia (dpi) were used for (A) tract tracing studies and behavioural analysis, (B) gene 
expression studies (RT-PCR) and (C) protein expression studies (immunohistochemistry, 
Western blots) and conventional histochemical analysis. Numbers of animals evaluated for 
each group and time points of animal sacrifice are also shown. On the far right, the 
rostrocaudal level, from which brain sections and tissue samples were harvested, is also 
illustrated. In addition to the animals shown in this scheme, additional sham-operated 
animals and ischemic animals not receiving intraventricular pumps were generated as control 
groups in some of the studies, as outlined in the Materials and Methods section. CB 
(cascade blue), BDA (biotinylated dextran amine), dpi (days post ischemia). 
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Figure 6. Experimental procedures and animal groups in VEGF experiment. 
 
Mice subjected to MCAO that were treated with VEGF or vehicle from 3 – 30 dpi were used 
for (A) tract tracing studies and behavioral analysis, (B) protein analysis studies (Western 
blots, gelatin zymography) and (C) conventional histochemical and immunohistochemical 
studies. Numbers of animals evaluated for each group and time point of animal sacrifice are 
shown. On the far right, the rostrocaudal level, from which brain sections and tissue samples 
were harvested, is presented. In addition to the experiments summarized in this scheme, 
additional sham-operated animals and ischemic animals not receiving intraventricular pumps 
were analyzed as additional control groups in a variety of studies (see Materials and 
Methods section). CB (cascade blue), BDA (biotinylated dextran amine) dpi (days post 
ischemia). 
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3.2. Induction of focal cerebral ischemia 
 
Animals were anesthetized with 1% isoflurane (30% O2, remainder N2O). 
Rectal temperature was maintained between 36.5 and 37.0°C using a feedback-
controlled heating system. Cerebral blood flow was analyzed by laser Doppler flow 
(LDF) recordings. 
 
Focal cerebral ischemia was induced using an intraluminal filament technique 
(Kilic et al., 2008). Briefly, a midline neck incision was made, and the left common 
and external carotid arteries were isolated and ligated. A microvascular clip was 
temporarily placed on the internal carotid artery. A silicon resin coated nylon 
monofilament was introduced through a small incision into the common carotid artery 
and advanced to the carotid bifurcation for MCAO. Thirty minutes later, reperfusion 
was initiated by monofilament removal. 
 
LDF changes were monitored for up to 30 min after reperfusion onset. In 
sham-operated animals, a surgical intervention was performed, in which the neck 
was opened and the common carotid artery was exposed, but left intact, while LDF 
recordings were performed (Fig. 7). After the surgery, wounds were carefully sutured, 
anaesthesia was discontinued and animals were placed back into their cages. 
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Figure 7. Middle cerebral artery occlusion and intraoperative LDF. 
 
Presentation of operative procedure of MCAO and of the intraoperative monitoring with laser 
Doppler flow (LDF). (a) LDF measurement during the operation as a control of blood flow 
reduction during the filament occlusion and after removing the filament. (b) Middle cerebral 
artery occlusion (MCAO) technique with introduction of a silicon filament in the common 
carotid and the in the internal carotid, causing occlusion at the base of the middle cerebral 
artery. (c-k) Intraoperative steps from the anesthesia induction up to the postoperative 
management. 
 
3.3. Intraventricular pump implantation 
 
Three days after surgery, animals were reanesthetized with 1% isofluran (30% 
O2, remainder N2O) and a cannula (Brain infusion kit 3, Alzet, Cupertino, CA) linked 
to miniosmotic pumps (Alzet 2004 or 1002; Alzet) filled with 0.9% NaCl or Epo 
(NeoRecormon, Roche, Basel, Switzerland) (1 or 10 I.U./day in 0.9% NaCl) or VEGF 
(0.004 µg or 0.02 µg / day in 0.9% NaCl) were implanted into the left-sided lateral 
ventricle through a burr hole (Kilic et al., 2010) (Fig. 8). Both types of pump 
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administered the therapy continuously in a dose of 0.25µl/hour. These pumps were 
left in place for up to 14 days (Alzet 1002) or 30 days (Alzet 2004) and then removed. 
 
 
 
 
Figure 8. Intraventricular pump implantation technique 
 
Fixation of the animal in the stereotactic frame afer the anesthetic procedures (A,B). Median 
incision of the skin fronto-occipital (C). Treppanation of 1mm diameter burr hole (0.5mm 
behind Bregma and and 1 mm left of the midline) (D). Intraventricular pump implantation 
(E,F). Subcutaneous internalisation of the pump (G). Suture of the skin and disinfection (H).  
 
3.4. Functional neurological tests 
 
Functional neurological recovery was assessed using a battery of tests at 
baseline and on days 3, 14 and 42 after MCAO. 
 
Grip strength test. The grip strength test consists of a spring balance coupled 
with a Newtonmeter (Medio-Line Spring Scale, metric, 300g, Pesola AG, Switzerland) 
that is attached to a triangular steel wire, which the animal instinctively grasps. When 
pulled by the tail, the animal exerts force on the steel wire (Kilic et al., 2010). Grip 
strength was evaluated at the right paretic forepaw, the left non-paretic forepaw 
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being wrapped with adhesive tape. Grip strength was evaluated five times on each 
test occasion, and mean values were calculated. From these data, percentage values 
(post-ischemic vs. pre-ischemic) were computed. Pre-ischemic and pre-treatment 
results did not differ between groups. 
 
RotaRod test. The RotaRod consists of a rotating drum with a speed 
accelerating from 6 to 40 rpm (Ugo Basile, model 47600, Comerio, Italy), which 
allows assessment of motor coordination skills (Kilic et al., 2010). Maximum speed is 
reached after 245 seconds, and the time at which the animal drops off the drum is 
evaluated (maximum testing time: 300 seconds). Measurements were performed five 
times each on the same occasion when grip strength was evaluated. For all five 
measurements, mean values were computed, from which percentage values (post-
ischemic vs. pre-ischemic) were calculated. Pre-ischemic and pre-treatment data did 
not differ between groups. 
 
Elevated O maze. The elevated O maze consists of a round 5.5 cm wide 
polyvinyl-chloride runway with an outer diameter of 46 cm, which is placed 40 cm 
above the floor and which detects spontaneous locomotor behaviour and correlates 
with fear and anxiety (Kilic et al., 2010). Two opposing 90° sectors are protected by 
16 cm high inner and outer walls made of polyvinyl-chloride (closed sectors). The 
remaining two 90° sectors are not protected by walls (open sectors). Animals were 
released in one of the closed sectors and observed for 10 min. The total number of 
zone entries - as correlate of motor activity - and the time spent in the unprotected 
sector - as correlate of exploration behaviour, fear and anxiety - were registered 
whenever the animal moved into a sector with all four paws. Assessments took place 
at baseline and at two and six weeks post-stroke. 
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3.5. Delivery of Cascade Blue-labelled dextran amine (CB) and 
biotinylated dextran amine (BDA) 
 
The anterograde tract tracer BDA has previously been used to evaluate 
pyramidal tract plasticity contralateral to the stroke in rats submitted to permanent 
focal cerebral ischemia (Wiessner et al., 2003). We adapted this method to mice, 
administering two different tracers, CB and BDA, in the motor cortex both ipsilateral 
(CB) and contralateral (BDA) to the stroke. For this purpose, cranial burr holes were 
drilled 0.5 mm rostral and 2.5 mm lateral to the bregma, via which deposits of 10% 
CB or 10% BDA (both 10,000 MW; Molecular Probes, diluted in 0.01 M phosphate-
buffered saline [PBS] at pH 7.2) were placed into the motor cortex by means of 
microsyringe injections six weeks after MCAO. As such, a total volume of 2.1 µl 
tracer was administered to each animal, which was injected in three equal deposits 
located rostrally, medially and caudally of the burr hole inside the motor cortex. For 
this purpose, the syringe was inserted into the brain at angles of 45°, 90° and 135° 
against the midline at a depth of 1.5mm (Z’Graggen et al., 1998). 
 
Ten days after the tracer injection, mice were transcardially perfused with 0.1 
M PBS pH 7.4 containing 100,000 I.U. heparin and 0.25% NaNO2 followed by 4% 
paraformaldehyde in 0.1 M PBS and 5% sucrose. Brains were removed and post-
fixed over-night in 4% paraformaldehyde in 0.1 M PBS and 5% sucrose and 
cryoprotected in increasing concentrations of sucrose (5%, 10% and 30%) over 3 
days. The tissue was then frozen with isopentan and cut into 20 µm and 40 µm thick 
coronal cryostat sections that were used for conventional and tract tracing 
histochemistry. 
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3.6. Immunohistochemistry 
 
For conventional immunohistochemistry, four animals per each therapy group 
in both Epo and VEGF studies were transcardially perfused with 0.9% NaCl at 14, 30 
and 52 days after the stroke. Brains were frozen on dry ice and cut on a cryostat into 
20 μm coronal sections (Kilic et al., 2010). Brain sections from the level of the 
bregma (i.e. midstriatum) were fixed in 4% paraformaldehyde (PFA) in 0.1 M PBS, 
rinsed, pre-treated for antigen retrieval with 0.01 M citrate buffer (pH 5.0), again 
rinsed and immersed for 1 h in 0.1 M PBS containing 0.3% Triton X-100 (PBS-T) and 
10% normal donkey serum. Four brain sections were analysed per animal. The tissue 
was incubated overnight at 4°C with monoclonal mouse anti-NeuN (MAB377; 
Chemicon), monoclonal rat anti-CD31 (#557355; BD Biosciences), monoclonal 
mouse anti-GFAP (green fluorescence actinic protein) Alexa Fluor 555 conjugated 
(#3656; Cell Signaling) for both studies. In the Epo study further 
immunohistochemistry with monoclonal rat anti-CD45 antigen (#550539; BD 
Pharmingen) and polyclonal rabbit anti-ionized calcium binding adaptor protein (Iba)-
1 (Wako Chemicals, Neuss, Germany) antibodies (diluted 1:100 in 0.1 M PBS) were 
performed. After detection with Cy3 or Cy2 conjugated secondary antibodies 
(Jackson ImmunoResearch, Suffolk, UK), sections were incubated with 4’-6-
diamidino-2-phenylindole (DAPI) and coverslipped. Alternatively, in some 
experiments (CD45, Iba1) biotinylated secondary antibodies were used that were 
detected with avidin-biotin kit (Vector Laboratories, Burlingame, CA) followed by 3,3’-
diaminobenzidine (DAB) (#D4418, Sigma, Missouri, USA) staining. 
 
Sections were evaluated under a fluorescence microscope (Olympus BX 41) 
connected to a CCD camera (CC12; Olympus). Surviving neurons (NeuN+), 
microvascular profiles (CD31+), reactive astroglia (GFAP+), leukocytes (CD45+) and 
microglia  (Iba1+) were analysed in a blinded way by counting numbers of cells or 
profiles in six defined regions of interests per striatum, both ipsi- and contralateral to 
the stroke (Kilic et al., 2005a, 2006). Mean values were calculated for all areas. With 
these data, neuronal survival, capillary density, astrogliosis, leukocyte infiltration and 
microglial activation were determined. In case of GFAP stainings, the overall area of 
scar tissue was outlined using the Soft imaging System Olympus Cell F Program. 
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Stereometric assessments of the degree of post-ischemic atrophy of the striatum and 
corpus callosum were done using modified Bielschowsky’s silver stainings as 
previously described (Ding et al., 2008). The borders of both structures were outlined 
and their surface analysed (in case of corpus callosum up to 1mm lateral to midline, 
thus reflecting areas on coronal brain sections [Bacigaluppi et al., 2009]). 
 
3.7. Immunohistochemistry for CB and BDA 
 
Brain sections of animals that had been transcardially perfused with PFA were 
rinsed three times for 10 min each in 50 mM Tris-buffered saline (pH 8.0) containing 
0.5% Triton X-100 (TBST). For detection of CB, sections were immersed overnight at 
4°C with polyclonal rabbit anti-Cascade Blue antibody (A-5760; Molecular Probes, 
1:100), diluted 1:100 in 50 mM TBST, followed by incubation for one hour at room 
temperature with a horseradish peroxidase (HRP)-labelled secondary anti-rabbit 
antibody (1:1000). For detection of BDA, sections were incubated overnight with 
avidin-biotin-peroxidase complex (ABC Elite; Vector Laboratories, Burlingame, CA). 
Reactions were visualized with DAB containing 0.4% ammonium sulfate and 0.004% 
H2O2. 
 
3.8. Analysis of corticorubral and corticobulbar projections  
 
The location of tracer deposits was checked at the levels of the needle tracks, 
thus ensuring that the motor cortex had indeed been injected in all animals. To 
account for variabilities in tracer uptake in different mice, we first evaluated the 
number of tracer-stained fibres in the corticospinal tract (CST) both at the level of the 
red nucleus and facial nucleus. For this purpose, two consecutive sections were 
analysed, counting the number of fibres crossing the sections in four regions of 
interest of 2865 µm² each that had been selected in the dorsolateral, ventrolateral, 
dorsomedial and ventromedial portion of the CST. By measuring the total area of the 
CST using the Cell Software image system (Olympus) connected to an Olympus 
BX42 microscope, we calculated the overall number of labelled pyramidal tract fibres, 
as described previously (Z’Graggen et. al., 1998). 
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Analysis of corticorubral projections. Corticorubral projections were evaluated 
at the level of the parvocellular red nucleus (bregma –3.0 to –3.5 mm). A 500 µm 
long intersection line was superimposed on the brain midline. Along that line those 
fibres crossing into the contralateral hemisphere in direction of the red nucleus were 
quantified. For each animal, the total number of fibres counted was normalized with 
the total number of labelled fibres in the CST and multiplied by 100, resulting in 
percent values of fibres crossing the midline. For both tracers two consecutive 
sections were analysed, from which mean values were determined. 
 
Analysis of corticobulbar projections. Corticobulbar projections were assessed 
at the level of the facial nucleus (bregma –5.8 to –6.3 mm). Two 500 µm long 
intersection lines were superimposed on the sections parallel to the midline, both 
representing tangents touching the most lateral extension of the pyramidal tract. 
Along both lines, those fibres crossing the lines in direction of the contralateral and 
ipsilateral facial nucleus were quantified. For each animal, the total number of fibres 
counted was normalized with the number of labelled fibres in the CST and multiplied 
by 100, resulting in percent values of fibres originating from the pyramidal tract. For 
both tracers two consecutive sections were evaluated, from which mean values were 
calculated. 
 
3.9. Gene expression analysis by RT-PCR 
 
For gene expression studies, mice were sacrificed at three different time-
points, namely at 3, 14 and 30 days after stroke by transcardiac perfusion with cold 
sterile 0.1 M PBS containing 0.01 M ethylenediaminetetraacetic acid (EDTA) (pH 
7.4). Brains were immediately removed and dissected on dry-ice. Blocks of tissue 
were cut from 2 mm rostral to 2 mm caudal to the bregma. From these blocks, 
samples were collected from six regions of interest: the motor cortex, the striatum 
and the parietal cortex both ipsilateral and contralateral to the stroke. All regions were 
processed in RNA-later RNA stabilization reagent (#76104; Qiagen, Hilden, 
Germany) and stored at -80° until RNA extraction. Brain tissue samples were 
homogenized and total RNA was isolated. 
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One µg of cDNA synthesized from 2 µg of total RNA was used for RT-PCR 
using pre-designed TaqMan low density arrays (TLDA) as previously described 
(Pluchino et al., 2008). Briefly, for each TLDA, there were eight separate loading 
ports that distributed the cDNA into a total of 48 wells, for a total of 384 different wells 
per card. Each well contains a specific primer and probe, capable of detecting one 
single gene. The gene cards evaluated 46 different genes (see Table 1) together with 
two housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and 18S ribosomal RNA. The latter is a mandatory control provided by the 
manufacturer. RT-PCR was processed with samples obtained from individual animals 
(avoiding pooling of the tissue) from each of the six regions of interest, each sample 
containing 10 µl cDNA (1 µg). 
 
RT-PCR was performed using the Applied Biosystems 7900HT Fast-Real-
Time PCR System. Gene cards were analysed using the threshold cycle (CT) relative 
quantification method. CT values were normalized for endogenous reference 
[ΔCT=CT (target gene) - CT (GAPDH)] and compared with a calibrator using the 
ΔΔCT formula [ΔΔCT= ΔCT (sample) – ΔCT (calibrator)]. In this study, we 
consistently used GAPDH as endogenous control. As calibrator sample we utilized a 
brain obtained from an untreated mouse of the same age, sex and strain. Data were 
presented using the logarithmic transformation of F.I. (fold induction) ratios between 
ischemic vehicle- and non-ischemic vehicle-treated mice (MCAO effect) and of ratios 
between ischemic Epo 10 I.U.-  and ischemic vehicle-treated mice (Epo effect) or 
VEGF- and ischemic vehicle-treated mice (VEGF effect). 
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Abbreviation Gene name Assay ID 
Inflammation genes 
IL-1b interleukin-1b Mm00434228_m1 
IL-6 interleukin-6 Mm00446190_m1 
Il4 interleukin-4 Mm00445259_m1 
eNOS nitric oxide synthase 3, endothelial Mm00435204_m1 
nNOS nitric oxide synthase 1, neuronal Mm00435175_m1 
iNOS nitric oxide synthase 2 , inducible Mm00440485_m1 
IFNγ interferon-γ Mm00801778_m1 
TNFα tumor necrosis factor-α Mm00443258_m1 
LIF leukemia inhibiting factor Mm00434761_m1 
CXCR4 chemokine receptor type 4 Mm99999055_m1 
GFAP glial fibrillary acidic protein Mm00546086_m1 
TGF-β 1 transforming growth factor, beta 1 Mm03024053_m1 
MMP-9 matrix metallopeptidase 9 Mm00442991_m1 
Fgf2 fibroblast growth factor II Mm00433287_m1 
VCAM-1 vascular cell adhesion molecule-1 Mm00449197_m1 
L1cam L1 cell adhesion molecule Mm00493049_m1 
Ncam1 neural cell adhesion molecule Mm03053534_s1 
Pro-plasticity (and survival modulating) genes 
GAP43 growth associated protein 43 Mm00500404_m1 
Basp1 brain abundant, membrane attached signal protein 1 Mm02344032_s1 
MARCKS myristoylated alanine rich protein kinase C substrate Mm02524303_s1 
SPRR1 small proline-rich protein 1A Mm01962902_s1 
Ptprz1 Protein tyrosine phosphatase, receptor type z Mm00478484_m1 
CNTF ciliary neurotrophic factor Mn00446373_m1 
BDNF brain-derived neurotrophic factor Mm00432069_m1 
Cdkn1a  cyclin-dependent kinase inhibitor 1A (P21) Mm01303209_m1 
NGF neuronal growth factor Mm00443039_m1 
IGF1 insulin-like growth factor 1 Mm01233960_m1 
KDR vascular endothelial growth factor receptor 2 Mm00440111_m1 
Nrp1 neuropilin 1 Mm00435372_m1 
c-Jun c-Jun oncogene Mm00495062_s1 
Pten phosphatase and tensin homolog Mm01212532_m1 
Nefl neurofilament light peptide Mm01315666_m1 
Bmp10 bone morphogenic protein 10 Mm01963768_s1 
Caspase-3 caspase-3 Mm01195085_m1 
Anti-plasticity genes 
sema 3a semaphorin 3 a Mm00436469_m1 
Ephrin A5 Eph receptor A5 Mm00433074_m1 
Ephrin B1 Eph receptor B1 Mm00557961_m1 
Versican versican Mm00490179_m1 
Ncan neurocan Mm00484007_m1 
Ntn1  netrin1 Mm00478484_m1 
Angiogenesis genes 
VEGF-B vascular endothelial growth factor-B Mm00442102_m1 
VEGF-A vascular endothelial growth factor-A Mm00437306_m1 
ANGP1 angiopoietin Mm00456503_m1 
Epo erythropoietin  Mm01202754_g1 
Epor erythropoietin receptor Mm00833882_m1 
HIF-1α hypoxia inducible factor, α-subunit Mm00468869_m1 
 
Table 1. List of genes whose expression pattern was investigated with regard to EPO 
or VEGF therapy after stroke. 
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3.10. Western blot analysis 
 
At postoperative days 3, 14, and 30 (for Epo study) and 3, 14, 30 and 42 (for 
VEGF study) four animals at each time point received a lethal dose of anaesthetic; 
and a 2 mm rostral-caudal section centred on bregma (as shown in the Fig 5 and 6) 
was dissected. The regions corresponding to the motor cortex and perilesional cortex 
both ipsi- and contralateral to the ischemic lesion were separated. Tissues belonging 
to the same group and the same time-point were pooled and further homogenized on 
ice for 30 sec, ultrasonicated for 2 min and treated with protease inhibitor cocktail and 
phosphatase inhibitor cocktail. The protein estimation was done by the Bradford 
method and controlled by stripping the blots and reprobing with actin antibody. For 
the Epo study equal amounts of each protein were loaded on 12% electrophoresis 
gels for SPRR1A mouse antibody (a kind gift of Prof. Strittmater, Yale University, 
USA) whereas for the VEGF study the amounts of protein were loaded on 5% (NG2 
proteoglycan), 7% (brevican) or 10% (ephrin B1, ephrin B2, c-Jun, activated 
caspase-3) gels. A sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) was performed, followed by protein transfer onto a PVDF membrane 
(Bio-Rad, Hercules, CA). Membranes were blocked in 5% non-fat milk in Tris-
buffered saline Tween 0.1% (TBS-T) for 1 hour at room temperature, washed in TBS-
T and incubated over night with mouse monoclonal SPRR1A (1:1000) in TBS-T (Epo 
study) or with monoclonal rabbit anti-total c-Jun (#9165; Cell Signaling), polyclonal 
rabbit anti-phospho-c-Jun (#9164S; Cell Signaling), polyclonal rabbit anti-activated 
caspase-3 (#9661; Cell Signaling), polyclonal rabbit anti-NG2 proteoglycan (H-300, 
sc-20162; Santa Cruz, Heidelberg, Germany), monoclonal mouse anti-brevican 
(610895; BD Biosciences), polyclonal rabbit anti-ephrin B1 (H70, sc-20723; Santa 
Cruz) and polyclonal goat anti-ephrin B2 (AF496; R&D Systems, Wiesbaden, 
Germany) antibody, diluted 1:1000 in TBS-Tw (VEGF study). The second day the 
membranes were washed and further incubated in blocking solution with peroxidase-
conjugated secondary antibodies for 1 hour at room temperature. Antibody binding 
was developed by a chemiluminescence kit according to the manufacturer’s protocol. 
The intensity of each signal was measured by Image J Program on three separate 
trials. Protein loading was controlled by means of β-actin blots using a polyclonal 
rabbit antibody (#4967; Cell Signaling). The relative levels of proteins were 
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normalized to their control both ipsi- and contralesional, at 3 days after the therapy 
was administered. The mean of three normalised values was calculated and 
graphically represented. 
 
3.11. MMP9 gelatin zymography 
 
Tissue samples from the same animals were processed for gelatin 
zymography using a previously published protocol (Zechariah et al., 2010). Brain 
samples were homogenized and lysated in NP-40 lysis buffer (150 mM NaCl, 50 mM 
Tris-HCl, 1% NP-40, pH 8.0) containing 5% protease inhibitor cocktail. Protein 
concentration was estimated using the DC Protein Assay Kit using an iMark 
microplate reader. Samples containing 5 µg protein were subjected to SDS-PAGE 
using 8% bis-acrylamide gel containing 0.1% gelatin (Sigma, Deisenhofen, 
Germany). After electrophoresis, gels were incubated for 1 hour at room temperature 
in modified enzymatic activation buffer (MEAB) (50 mM Tris-HCl, 6 mM CaCl2, 1.5 
µM ZnCl2, pH 7.4) containing 2.5% Triton X-100, followed by overnight incubation in 
MEAB. The next day, gels were stained in Coomassie brilliant blue R-250. Gels were 
dried and digitized. Three experiments were run for each tissue sample. 
3.12. Statistical analysis 
Behavioural tests were analysed by means of two-way repeated measurement 
analysis of variance (ANOVA; treatment vs time) at three different time-points starting 
at 3 days post-stroke, at the time of Epo adnminstration, and at the time of VEGF 
administration. For those tests in which significant treatment or treatment by time 
interaction effects were noticed (at 0.05 level), one-way ANOVAs were done for each 
time-point, using least significant differences (LSD) tests for post-hoc analyses. Tract 
tracer histological data were evaluated by one-way ANOVA (comparison between n ≥ 
3 groups). Immunohistological data, gene and protein expression studies were 
analysed by two-way ANOVA (treatment vs time). Whenever a treatment effect or 
treatment by time interaction effect was present at the 0.05 level, two-tailed t-tests 
were performed for each time-point. 
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4. RESULTS 
 
4.1. Post-acute delivery of Epo improves post-ischemic 
neurological recovery 
 
To evaluate whether Epo influences neurological recovery in the post-acute 
stroke phase, mice subjected to 30 minutes of left-sided MCAO were 
intracerebroventricularly (i.c.v.) treated with vehicle or Epo (1 or 10 I.U./day) starting 
at 3 days post-ischemia (dpi). LDF measurements and body weight did not show any 
differences between groups (Fig. 9A, B). In all groups, LDF decreased to ~15-20% of 
baseline during MCAO, followed by a rapid restoration of blood flow after reperfusion 
(Fig. 9A). Except for a transient mild reduction in body weight at 3 dpi (< 10%) that 
was similar in all groups, no abnormalities in weight development were seen (Fig. 
9B).  
 
The surgical implantation of the pump and the pump itself did not create any 
serious complication during the whole period of treatment of the animals. 24 hours 
after implantation no differences were observed between the groups with regard to 
complications or acceptance of the pump by the animals. All the pumps were 
removed on day 30 post-ischemia, after testing of behaviour skills. Towards the last 
week of treatment a small irritation of the skin in the pump vicinity was observed, an 
irritation that appeared in all groups independent of treatment and that was treated by 
cleaning and desinfection with Betadine. Two animals removed their pumps before 
day 30, and were removed from the experiment. 
 
Neurological recovery was investigated by grip strength (Fig. 9C) and Rotarod 
(Fig. 9D) tests, which assess motor force of the paretic right forelimb and motor 
coordination. Significant reductions in motor force (Fig. 9C) and coordination skills 
(Fig. 9D) occurred in animals submitted to 30 minutes MCAO. In vehicle-treated 
ischemic animals and in animals receiving Epo at the low dosage (1 I.U./day), grip 
strength and RotaRod performance remained largely unchanged over the entire 42-
day observation period (Fig. 9C, D). In animals treated with Epo at the higher dosage 
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(10 I.U./day), progressive improvement of motor force and coordination were 
observed at 14 and 42 dpi (Fig. 9C, D). Elevated O maze tests did not show any 
differences in spontaneous locomotor activity and exploration behaviour between 
groups (Fig. 9E, F). 
 
Figure 9. Delayed delivery of Epo at 10 I.U./day, but not 1 I.U./day promotes post-
ischemic functional recovery. 
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(A) LDF recordings above the core of the MCA territory, (B) body weight, (C) grip strength of 
the lesion-contralateral right paretic forepaw, (D) coordination skills evaluated by RotaRod 
tests, (E) locomotor activity, and (F) exploration behaviour. Note that motor force (C) and 
coordination skills (D), which were compromised by the stroke, did not exhibit any major 
improvements over time in vehicle-treated mice and mice receiving Epo at a dosage of 1 
I.U./kg, but progressively improved over 14 to 42 days in animals treated with Epo at a 10 
I.U./kg dosage. Spontaneous locomotor activity (E) and exploration behaviour (F) were not 
influenced by Epo. LDF recordings (A) and body weight (B) did not differ between groups. 
Data are mean values ± S.D. Data were analysed by two-way repeated measures ANOVA, 
followed by one-way ANOVA / LSD tests for each time-point. +P< 0.05 compared with pre-
ischemic baseline; *P< 0.05/ **P< 0.01 compared with vehicle-treated ischemic mice. 
 
4.2. Post-acute delivery of Epo promotes peri-lesional tissue 
remodeling 
 
In order to assess whether the post-acute delivery of Epo influences the 
remodeling of ischemic brain tissue, histochemical studies were performed. 
Immunohistochemical stainings for the neuronal marker NeuN revealed slowly 
progressive degeneration in the striatum of vehicle-treated ischemic mice, reflected 
by a continuous decline of surviving neurons (Fig. 10A) and striatal atrophy (Fig. 10B) 
that developed between 14 and 52 dpi. Notably, Epo delivered at the higher dosage 
(10 I.U./ day) significantly increased neuronal survival (Fig. 10A), at the same time 
preventing striatal shrinkage (Fig. 10B). The thickness of the corpus callosum was 
not changed by Epo treatment (Fig. 10C). 
 
To define Epo’s impact on angiogenesis, an accompaniment of successful 
neurovascular remodeling (Hermann and Zechariah, 2010), immunohistochemical 
stainings for the endothelial marker CD31 were assessed. Focal cerebral ischemia 
was followed by an increase in the density of CD31+ striatal capillaries to ~200% of 
baseline in vehicle-treated ischemic mice that persisted for up to 30 days after MCAO 
(Fig. 10D). Epo further increased the capillary density, which remained elevated until 
the end of the experiments, i.e. at 52 dpi (Fig. 10D). 
To evaluate how Epo influences the astroglial responses to stroke, 
immunohistochemistry for the astroglial marker GFAP were analysed. In vehicle-
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treated ischemic mice, focal cerebral ischemia corresponded with reactive astrocytes, 
which were dispersed throughout the middle cerebral artery territory and persisted 
over the observation period of 52 dpi (Fig. 10E). During Epo therapy, reactive 
astrogliosis was less pronounced (Fig. 10E). However, this glial-inhibitory effect 
disappeared after pump removal, i.e., at 52 dpi, when reactive astrogliosis again 
returned to levels similar to those of vehicle-treated ischemic animals (Fig. 10E). 
 
In the most lateral portion of the striatum, a localized scar characterized by 
densely packed GFAP+ astrocytes developed beginning at 30 days, more clearly 
distinguishable at 52 dpi in vehicle-treated mice (Fig. 10F). Epo also reduced the size 
of this latter scar (Fig. 10F). 
 
Looking at the relation between Epo and inflammatory reaction after stroke by 
means of leukocyte infiltration (Fig. 10G) and microglial activation (Fig. 10H) showed 
that Epo may reduce inflammation in the acute to post-acute phase after stroke, but 
on a long term (53 dpi) it causes a significant increase in leucocyte infiltration of the 
ischemic striatum. 
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Figure 10. Epo promotes peri-lesional tissue remodelling and exerts anti-
inflammatory actions 
 
(A) Surviving neurons in ischemic striatum evaluated by NeuN immunohistochemistry, (B) striatal 
atrophy and (C) corpus callosum atrophy examined by Bielschowski stainings, (D) angiogenesis 
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assessed by CD31 immunohistochemistry, (E) diffuse astrocytosis at various time points and (F) 
circumscribed scar formation in the most lateral striatum at 52 dpi revealed by GFAP 
immunohistochemistry, as well as (G) leukocyte infiltration and (H) microglial activation analysed by 
CD45 and Iba1 immunohistochemistry. Note that Epo increased neuronal survival at 52 dpi (A), 
diminished progressive brain atrophy (B) without influencing corpus callosum thickness (C), 
promoted angiogenesis (D), reduced diffuse astrocytosis (E) and glial scar formation (F) and inhibited 
leukocyte infiltration (G), without affecting microglial activation (H). Photomicrographs are also 
shown that were taken at 52 dpi (A-D, F) or 14 dpi (E,G,H). Data are mean values ± S.D. Data were 
analysed by two-way ANOVA followed by two-tailed t-tests for individual time points. *P< 0.05/ 
**P< 0.01 compared with vehicle-treated ischemic mice. Bar, 200 µm (B, F) /50 µm (C) /20 µm (A, 
D, E, G, H). 
 
4.3. Analysis of lesion-remote plasticity using anterograde tract-
tracers 
 
Because the pyramidal tract crosses the middle cerebral artery territory, which 
was affected by ischemia, we wanted to understand how Epo influences pyramidal 
tract degeneration and plasticity both ipsilateral and contralateral to the stroke. To 
this end, we administered two dextrane conjugates, CB and BDA, into both motor 
cortices. There were no relevant differences between groups in the locations of the 
injection sites. In all mice, the injection sites covered the more caudal forelimb area 
and rostral hindlimb area of the primary motor cortex without relevant spreading of 
tracer deposits into subcortical structures. 
 
To analyse whether Epo influenced the survival of CST fibres distant to the 
stroke lesion, we counted CB-labelled fibres in the cerebral peduncle both at the level 
of the red nucleus and facial nucleus. This quantification did not reveal any 
differences between vehicle- and Epo-treated mice (red nucleus level: 44453±9944 
vs. 44629±5509 fibres / facial nucleus level: 19188±7383 vs. 19943±1592 fibres, 
respectively), thus indicating that Epo did not influence the survival of descending 
pyramidal tract axons. Similar to CB-labelled fibres in the ipsilesional pyramidal tract, 
BDA-labelled fibres in the contralesional CST did not differ between vehicle- and 
Epo-treated mice. Similar to the total number of fibres, the overall size of the 
pyramidal tract, analysed on coronal sections at the bulbar level, was not changed by 
60 
 
Epo, neither ipsilesional (0.06±0.02 vs. 0.07±0.03 mm2), nor contralesional 
(0.07±0.01 vs. 0.06±0.02 mm2) to the stroke. As such, the corticospinal system was 
not affected by secondary degeneration. 
 
4.4. Epo promotes contralesional, but not ipsilesional 
corticorubral plasticity 
 
CB- and BDA-stained fibres originating from the cerebral peduncle converted 
dorsomedially at mesencephalic levels, terminating as previously described 
(Z’Graggen et al., 1998; Brown, 2007) in the parvocellular part of the ipsilateral red 
nucleus. At this level, we quantified the number of fibres crossing the midline towards 
the contralesional red nucleus. Our results revealed a moderate (though not 
significant) increase in the percentage of BDA-labelled midline crossing fibres derived 
from the ipsilesional CST upon MCAO. On the other hand, the percentage of BDA-
labelled midline crossing fibres originating from the contralesional CST remained 
unchanged (Fig. 11). Importantly, Epo significantly promoted the outgrowth of midline 
crossing fibres from the contralesional CST, without influencing the plasticity of 
ipsilesional CST fibres (Fig. 11). 
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Figure 11. Epo promotes contralesional, but not ipsilesional corticorubral plasticity.  
Epo promotes contralesional, but not ipsilesional corticorubral plasticity. 
 
Tract tracing analysis of corticorubral projections ipsilateral and contralateral to the stroke in 
mice receiving Cascade Blue (CB) and biotinylated dextran amine (BDA) injections into the 
ipsilesional and contralesional motor cortex (for experimental procedures see (A)). Percent of 
midline crossing fibers to (B) the contralesional red nucleus (RN) traced by CB and (C) the 
ipsilesional, denervated RN traced by BDA. Note that the percentage of midline crossing 
fibres after ipsilesional CB injection moderately, but not significantly, increased in response 
to stroke (B). Interestingly, Epo did not further elevate the percentage of midline-crossing 
fibres of the ipsilesional pyramidal tract (B), but increased contralesional pyramidal tract 
sprouting across the midline, resulting in fibre outgrowth towards the denervated lesion-sided 
RN (C). (D) Photomicrographs of representative ischemic vehicle-treated and Epo-treated 
mice illustrating BDA traced corticorubral fibers intersecting the midline between both RN. 
Note that the denervated RN receives more BDA traced fibers after Epo than after vehicle 
delivery. Data are means ± S.D. Data were analysed by one way ANOVA followed by LSD 
tests. +P< 0.05 compared with vehicle-treated non-ischemic mice. *P< 0.05 compared with 
vehicle-treated ischemic mice. 
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4.5. Epo enhances contralesional, but not ipsilesional 
corticobulbar plasticity  
 
At the midpontine level, two fibre bundles originated from the CST innervate 
the ipsilesional and contralesional facial nucleus. At this level, we counted the fibres 
leaving the CST in direction of both facial nuclei, evaluating fibres crossing two 
intersection lines. Our data showed that focal cerebral ischemia significantly 
increased the density of fibres originating from the CB-labelled ipsilesional CST 
innervating the ipsilesional facial nucleus, without affecting the density of fibres 
derived from the BDA-labelled contralesional CST (Fig. 12). Epo significantly 
increased the sprouting of BDA-labelled contralesional CST axons to the 
contralesional facial nucleus, at the same time mildly but non-significantly (p=0.07) 
reducing facial nucleus projections derived from the CB-labelled ipsilesional CST 
(Fig. 12).  
 
 
63 
 
 
Figure 12. Epo increases contralesional corticobulbar plasticity without influencing 
ipsilesional corticobulbar plasticity that is increased by the stroke. 
 
Tract tracing analysis of corticobulbar projections ipsilateral and contralateral to the stroke at 
the level of the facial nucleus (FN) in mice receiving CB and BDA injections into the 
ipsilesional and contralesional motor cortex (experimental procedures shown in (A)). Percent 
of fibers leaving the pyramidal tract in direction of the ipsilesional and contralesional FN 
traced by (B) CB and (C) BDA. Note that the percentage of fibres projecting to the 
ipsilesional FN after CB injection into the lesion-sided motor cortex significantly increased in 
response to stroke (B). Interestingly, Epo did not further strengthen this ipsilesional 
projection, but rather reduced it (B), at the same time increasing the percentage of BDA 
stained contralesional pyramidal tract fibres innervating the contralesional FN (C). (D) 
Microphotographs of representative ischemic vehicle-treated and Epo-treated mice showing 
BDA-traced corticobulbar fibers crossing the intersection lines on both sides of the pyramidal 
tracts. Note that Epo increased fibre outgrowth towards the contralesional FN. Data are 
means ± S.D. Data were analysed by one way ANOVA followed by LSD tests. +P< 0.05/ ++P< 
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0.01 compared with vehicle-treated non-ischemic mice. *P< 0.05 compared with vehicle-
treated ischemic mice. 
 
4.6. Post-ischemic remodelling by Epo involves anti-inflammatory 
effects 
 
To elucidate the mechanisms underlying Epo’s restorative actions, we 
performed semi-quantitative RT-PCR-based gene expression profiling, investigating 
a series of acute and chronic inflammation markers (for complete list see Table 1) in 
the striatum (Str), motor cortex (MCx) and parietal cortex (ParCx) of both 
hemispheres. As expected, stroke robustly increased several inflammation markers 
in the ischemic hemisphere, including interleukin (IL)-1β, tumour necrosis factor 
(TNF)-α, leukemia-inhibitory factor (LIF), transforming growth factor (TGF)-β, IL-6, 
GFAP and inducible NO synthase (iNOS) (Fig. 13). Epo significantly reduced all 
these mRNAs in the ipsilesional hemisphere, and to a lesser extent in the 
contralesional hemisphere (Fig. 13). 
 
In order to identify immune cells involved in the anti-inflammatory action of 
Epo, immunostainings for the leukocyte marker CD45 and microglia marker Iba1 
were performed. Epo significantly reduced the brain infiltration of CD45+ leukocytes 
(Fig. 10G), but not the presence of Iba1+ microglia (Fig. 10H) in the ischemic 
striatum. In the contralesional hemisphere, neither Iba1+ microglia, nor CD45+ 
leukocytes were seen. These data indicate that attenuation of leukocyte recruitment, 
besides reduced reactive astrogliosis, may contribute to Epo’s anti-inflammatory 
actions. 
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Figure 13. Temporospatial analysis of anti-inflammatory effects of Epo in the 
ipsilesional and contralesional hemispheres. 
 
Semi-quantitative rt-PCR analysis summarizing the expression of inflammation-related genes 
in the striatum (Str), motor cortex (MCx) and parietal cortex (ParCx) at 3, 14 and 30 dpi. 
Gene expression changes induced by MCAO (A,B) and by Epo (C,D) are depicted. 
Throughout the time period examined, from 3 – 30 dpi, focal cerebral ischemia increased the 
mRNA levels of Il-1β, TNF-α, Lif, TGFβ, Il-6, GFAP and iNOS (A,B). Epo attenuated the 
expression of all seven genes at 14 dpi, most strongly in the ischemic hemisphere (C) but 
this effect was less pronounced also in the contralesional hemisphere (D). Data are 
logarithmic ratios of fold inductions after MCAO vs. sham surgery (A,B) and Epo vs. vehicle 
treatment (C,D). Data were analysed by two-way ANOVA. *P<0.05 compared with vehicle-
treated ischemic mice. 
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4.7. Modulation of pro-plasticity and anti-plasticity genes by Epo 
 
To better understand how Epo influences brain plasticity both ipsilateral and 
contralateral to the stroke, additional RT-PCR studies were performed, using 
plasticity-promoting and -inhibitory genes that were previously described to be 
induced in the first days or weeks after stroke (Carmichael and Li, 2006; Table 1).  
 
Induction of ischemia was accompanied by a robust upregulation of the 
mRNAs of the following pro-plasticity genes in the ischemic but not the contralesional 
hemisphere between 3 and 30 dpi: small proline-rich protein (SPRR)1, insulin-like 
growth factor (IGF)-1, brain-derived neurotrophic factor (BDNF), vascular endothelial 
growth factor receptor-2 (KDR) and myristoylated alanine-rich C-kinase substrate 
(MARCKS)  (Fig. 14). On the other hand, no comparable unequivocal pattern in the 
regulation of anti-plasticity mRNAs was observed (Fig. 14). 
 
Whereas Epo diminished the expression of different pro-plasticity genes (i.e., 
IGF-1 and KDR) in the ischemic hemisphere at 14 but not 30 dpi, in the non-ischemic 
hemisphere Epo downregulated the anti-plasticity mRNAs neurocan and ephrin B1 
and upregulated the pro-plasticity SPRR1 mRNA at 14 and 30 dpi (Fig. 14). 
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Figure 14. Temporospatial analysis of plasticity-promoting and -inhibiting effects of 
Epo in the ipsilesional and contralesional hemisphere. Semi-quantitative RT-PCR 
analysis.  
 
The expression of pro-plasticity and anti-plasticity genes that were regulated by the stroke in 
the striatum (Str), motor cortex (MCx) and parietal cortex (ParCx) at 3, 14 and 30 dpi are 
summarized. Gene expression changes induced by MCAO (A,B) and by Epo (C,D) are 
summarized. Throughout the time period examined, focal cerebral ischemia elevated the 
mRNA levels of different pro-plasticity genes, namely SPRR1 and IGF-1, in the ischemic 
hemisphere (A). Interestingly, Epo reduced the expression of SPRR1, IGF-1, BDNF and 
KDR at 14 dpi in the ischemic hemisphere (A), at the same time downregulating the anti-
plasticity genes neurocan and ephrin-B1 more clearly in the contralesional hemisphere (B) 
as compared to the ipsilesional hemisphere (A). Data are logarithmic ratios of fold inductions 
after MCAO vs. sham surgery (A,B) and Epo vs. vehicle treatment (C,D). Data were 
analysed by two-way ANOVA. *P< 0.05 compared with vehicle-treated ischemic mice. 
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Figure 15. Epo downregulates SPRR1A protein in the ipsilesional motor cortex. 
 
Western blot analysis shows reduced SPRR1A in Epo- as compared with vehicle-treated 
mice at 14 and 30 dpi. Protein loading was controlled by reprobing the blots with a β-actin 
antibody. SPRR1A levels were densitometrically analysed. Data are mean values ± S.D. 
Data were evaluated by two-way ANOVA followed by two-tailed t-tests for both time points. 
**P< 0.01 compared with vehicle-treated ischemic mice.  
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4.8. Neurological recovery is improved by post-acute VEGF 
delivery 
 
In order to evaluate whether VEGF promotes neurological recovery when 
administered in the post-acute stroke phase, mice subjected to 30 min of left-sided 
MCAO were intracerebroventricularly (i.c.v.) treated with vehicle or VEGF (0.004 or 
0.02 µg/day) starting at 3 dpi. LDF, which was recorded to evaluate changes in 
cerebral blood flow (Fig. 16A), and body weight (Fig. 16B) did not reveal any 
differences between groups. Reproducible ischemias were followed by stable 
reperfusions to levels slightly above baseline values (Fig. 16A). Only a mild reduction 
in body weight was noticed at 3 dpi in all groups (~10%), from which animals quickly 
recovered within 14 dpi (Fig. 16B). 
 
Motor recovery was investigated by grip strength (Fig. 16C) and Rotarod (Fig. 
16D) tests. Reductions in motor force of the contralesional right forelimb (Fig. 16C) 
and coordination skills (Fig. 16D) were noticed in animals subjected to 30 min MCAO. 
In vehicle-treated ischemic animals and animals receiving VEGF at low dosage 
(0.004 µg/day), deficits in motor force and coordination persisted over the 
observation period of 6 weeks (Fig. 16C, D) 
 
 In animals treated with 0.02 µg/day VEGF, on the other hand, grip strength 
and coordination skills progressively improved during that time interval, reaching 
levels significantly above vehicle-treated animals at 42 dpi (Fig. 16C, D). 
Spontaneous locomotor activity and exploration behavior, which were evaluated by 
elevated O maze tests, did not differ between groups (Fig. 16E, F). 
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Figure 16. Delayed delivery of VEGF at 0.02 µg / day, but not 0.004 µg / day 
promotes post-ischemic neurological recovery. 
 
(A) LDF recordings above the core of the MCA territory, (B) body weight, (C) grip strength of 
the lesion-contralateral right paretic forepaw, and (D) coordination skills evaluated by 
RotaRod tests. Note that grip strength (C) and coordination skills (D) did not exhibit any 
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major improvements over time in vehicle-treated mice and mice receiving VEGF at a dosage 
of 0.004 µg / day, but progressively increased over 14 to 42 days in animals treated with 0.02 
µg VEGF / day. LDF recordings (A) and body weight (B) did not differ between the groups. 
There was no difference in between groups regarding locomotor activity (E) and exploration 
behavior (F). Data are mean values ± S.D. (n=10 animals per group). Data were analyzed by 
two-way repeated measures ANOVA, followed by one-way ANOVA / LSD tests for each 
time-point. #p< 0.05 compared with pre-ischemic baseline; *p< 0.05 compared with vehicle-
treated ischemic mice. 
 
4.9. VEGF promotes angiogenesis predominantly in the ischemic 
hemisphere, at the same time preventing secondary neuronal 
degeneration 
 
To elucidate how VEGF influences new vessel formation, the density of brain 
capillaries was analyzed by immunohistochemistry for CD31, a marker for endothelial 
cells. Whereas brain capillary density did not change in the perilesional tissue of 
vehicle-treated mice, the density of cerebral microvessels increased to ~200% of 
baseline within 52 dpi in mice receiving VEGF at the higher dosage (0.02 µg/day) 
(Fig. 17A). Notably, capillary density in the contralesional striatum was only mildly 
influenced by VEGF (Fig. 17B). 
 
To assess how VEGF affects neuronal survival, which closely accompanies 
angiogenesis in the perilesional brain tissue (Sun et al., 2003; Hermann and 
Zechariah, 2009), immunohistochemistry analyses for the neuronal marker NeuN 
were analyzed. Slowly progressive degeneration was noticed in the striatum of 
vehicle-treated mice, reflected by a loss of surviving neurons (Fig. 17C) and 
progressive striatal atrophy (Fig. 17D). Notably, VEGF significantly increased 
neuronal survival at 14 dpi (Fig. 17C), translating into reduced shrinkage of the 
ischemic striatum at 52 dpi (Fig. 17D).  
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Figure 17. VEGF prevents secondary neurodegeneration and induces angiogenesis. 
 
(A) capillary density in ischemic striatum assessed by CD31 immunohistochemistry and (B) 
in non-ischemic striatum. (C) Density of surviving neurons in ischemic striatum evaluated by 
NeuN immunohistochemistry, (D) striatal shrinkage examined by Bielschowsky staining, (E) 
corpus callosum atrophy evaluated by Bielschowsky staining (F) Glial scar formation. Note 
that VEGF increases neuronal survival at 14 dpi (C), translating into reduced brain atrophy at 
52 dpi (D). In addition, VEGF promotes angiogenesis (A) and mildly increases corpus 
callosum thickness (E). Photomicrographs were also taken at 14 dpi (C) or 52 dpi (A, B, D, 
E, F). Data are mean values ± S.D. (n=4-8 animals per group). Data were analyzed by two-
way ANOVA followed by two-tailed t-tests for individual time points or two-tailed t-tests, as 
appropriate. *p< 0.05/ **p< 0.01 compared with vehicle-treated ischemic mice. Bar, 200 µm 
(D)/ 50 µm (E, F)/ 20 µm (C). 
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4.10. VEGF promotes contralesional, but not ipsilesional pyramidal 
tract plasticity 
 
To analyze how VEGF influences pyramidal tract remodeling both ipsilateral 
and contralateral to the stroke, two dextran conjugates, CB and BDA, were 
administered into both motor cortices. Injection sites covered the more caudal 
forelimb area and rostral hindlimb area of the primary motor cortex. The number of 
anterogradely labeled axons in the pyramidal tracts did not differ between vehicle-
treated and VEGF-treated mice, neither ipsilateral nor contralateral to the stroke 
(level of red nucleus: 44,453±19,944 vs. 44,554±12,393 fibers; level of facial nucleus: 
19,188±7,383 vs. 25,408±16,306 fibers [on lesioned side] for vehicle and VEGF, 
respectively). The area covered by the pyramidal tract was also similar in both groups 
(level of facial nucleus: 0.05±0.02 vs. 0.07±0.04 mm2 [on lesioned side]; 0.06±0.01 
vs. 0.07±0.02 mm2 [contralateral to stroke] for vehicle and VEGF, respectively), 
indicating that neither ischemia nor VEGF influenced the survival of corticospinal 
axons.  
 
Importantly, VEGF promoted the sprouting of labeled fibers branching off the 
contralesional, but not ipsilesional pyramidal tract at the level of the red and facial 
nuclei. As such, the number of labeled midline-crossing fibers originating from the 
BDA-labeled contralesional pyramidal tract was significantly increased at the levels of 
the red and facial nucleus, as was the number of fibers branching off the 
contralesional pyramidal tract in direction of the contralesional facial nucleus (Figs. 
18, 19). Interestingly, VEGF did not affect the sprouting of CB-labeled ipsilesional 
pyramidal tract fibers that were increased in ischemic as compared to sham-operated 
non-ischemic mice, neither at the rubral nor the bulbar level (Figs. 18, 19). 
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Figure 18. VEGF promotes contralesional, but not ipsilesional corticobulbar plasticity.  
 
Tract tracing analysis at the level of the facial nucleus (FN) in mice receiving Cascade Blue 
(CB) and biotinylated dextran amine (BDA) injections into the ipsilesional and contralesional 
motor cortex (for placement of tracer injections see (A)). Percent of fibers leaving the 
pyramidal tract in direction to the ipsilesional and contralesional FN traced by (B) CB and (C) 
BDA. Note that the percentage of fibers projecting to the ipsilesional FN after CB injection 
into the lesion-sided motor cortex significantly increases in response to stroke (B). 
Interestingly, VEGF does not further strengthen this ipsilesional projection (B), but increases 
the percentage of BDA stained contralesional pyramidal tract fibers innervating the 
ipsilesional and contralesional FN (C). (D) Microphotographs of representative ischemic 
vehicle-treated and VEGF-treated mice showing BDA-traced corticobulbar fibers crossing the 
intersection lines (superimposed in blue) on both sides of the brain. Note that VEGF 
increases axonal sprouting towards both FN (intersecting fibers labeled with dots). Data are 
means ± S.D. (n=10 animals per group [ischemic vehicle, ischemic VEGF] / n=4 animals per 
group [non-ischemic vehicle]). Data were analyzed by one way ANOVA followed by LSD 
tests. #p< 0.05 compared with vehicle-treated non-ischemic mice. *p< 0.05 compared with 
vehicle-treated ischemic mice. 
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Figure 19. VEGF stimulates corticorubral plasticity. 
 
VEGF promotes contralesional, but not ipsilesional corticorubral plasticity. Tract tracing 
analysis of corticorubral projections ipsilateral and contralateral to the stroke in mice 
receiving Cascade Blue (CB) and biotinylated dextran amine (BDA) injections into the 
ipsilesional and contralesional motor cortex (for experimental procedures see (A)). Percent of 
midline crossing fibers to (B) the contralesional red nucleus (RN) traced by CB and (C) the 
ipsilesional, denervated RN traced by BDA. Note that the percentage of midline crossing 
fibres after ipsilesional CB injection increased moderately, though not significantly, in 
response to stroke (B). (D) Photomicrographs of representative ischemic vehicle-treated and 
VEGF-treated mice illustrating BDA traced corticorubral fibers intersecting the midline 
between the two RNs. Note that the denervated RN receives more BDA traced fibers after 
VEGF than after vehicle delivery. Data are means ± S.D. Data were analysed by one way 
ANOVA followed by LSD tests. +P< 0.05 compared with vehicle-treated non-ischemic mice. 
*P< 0.05 compared with vehicle-treated ischemic mice. 
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4.11. Brain reorganization involves deactivation of matrix 
metalloproteinase MMP9 in the ischemic, but not 
contralesional hemisphere 
 
To elucidate mechanisms underlying the reorganization of the brain tissue 
both ipsilateral and contralateral to the stroke, we examined the activation of MMP9 
by gelatin zymography. Activation of MMP9 was noticed throughout the ischemic 
hemisphere (i.e., in striatum, parietal cortex and motor cortex) over the observation 
period of 42 days (shown for striatum in Fig. 20A). VEGF significantly attenuated 
MMP9 activity (Fig. 20A). Contralateral to the stroke, a mild activation of MMP9 was 
found at 3 dpi, but not at later time points (not shown). To clarify whether regulation 
of MMP9 takes place at the gene expression level, RT-PCR for mmp9 was analyzed. 
Significantly reduced mRNA levels for mmp9 were observed throughout the brain, 
both ipsilateral and contralateral to the stroke (Fig. 23), indicating that VEGF-induced 
MMP9 inhibition involves some transcription effects. 
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Figure 20. VEGF deactivates MMP9, activates c-Jun and prevents caspase-3-
dependent apoptotic cell death.  
 
Gelatin zymography for MMP9 (A), Western blot analysis using antibodies detecting total and 
phosphorylated c-Jun (B) and cleaved (i.e., activated) caspase-3 (C), as well as DNA 
fragmentation studies using TUNEL (D). For A-C, tissue samples from the striatum were 
used. In (B) and (C), data are presented as optical densities. Protein loading was controlled 
with a β-actin antibody. Representative zymographies, blots and TUNEL stainings are 
shown. Data are means ± SD (n=3 zymographies and Western blots [A-C] / n=4 animals per 
group). Data were analyzed by two-way ANOVA followed by two-tailed t-tests for individual 
time-points. **p< 0.01 compared with vehicle-treated ischemic mice. Bar, 45 µm. 
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4.12. VEGF modulates the transcription factor c-Jun and inhibits 
apoptotic cell death 
 
To characterize mechanisms underlying perilesional tissue remodeling, 
Western blots for the transcription factor c-Jun and the executioner caspase-3 were 
evaluated using antibodies detecting both total and phosphorylated c-Jun as well as 
cleaved (i.e., activated) caspase-3 using tissue samples obtained from the 
ipsilesional and contralesional striatum. c-Jun was abundant in ischemic brain tissue 
(Fig. 20B). Although the expression of total (i.e., phosphorylated and non-
phosphorylated) c-Jun was downregulated by VEGF in the ischemic (Fig. 20B), but 
not non-ischemic (not shown) striatum at 14 dpi, VEGF increased the percentage of 
phosphorylated c-Jun in the ipsilesional brain tissue (Fig. 20B). 
 
 In accordance with the promotion of neuronal survival, caspase-3 activity was 
reduced by VEGF in the ischemic striatum at 14 and 30 dpi (Fig. 20C), as was DNA-
fragmentation evaluated by TUNEL at 14 dpi (Fig. 20D). To evaluate whether cell 
death-associated proteins were regulated on the transcriptional level, RT-PCR was 
performed. Similar to mmp9, the mRNAs for c-jun, the cell cycle gene cdkn1, and 
caspase-3 were downregulated both ipsilateral and contralateral to the stroke (Fig. 
21), indicating that transcriptional regulation of cell death genes reflects a bilateral 
response of the brain, whereas protein translation and activation is regionally 
confined to perilesional areas. 
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Figure 21. Effect of VEGF upon gene expression of mmp9, c-jun, cdkn1 and 
caspase 3. Semi-quantitative RT-PCR analysis.  
 
Summarizing the expression of mmp9, c-jun, cdkn1 and caspase 3 genes that were 
regulated by the stroke in the striatum (Str), motor cortex (MCx) and parietal cortex (ParCx) 
at 3, 14 and 30 dpi. Both gene expression changes induced by MCAO (A,B) and by VEGF 
(C,D) are summarized. Throughout the time period examined, focal cerebral ischemia 
elevated the mRNA levels of mmp9, c-jun, cdkn1 and caspase 3 (A). VEGF reduced the 
expression of mmp9, c-jun, cdkn1 and caspase 3 at 30 dpi in the ischemic hemisphere (C) 
and non-ischemic hemisphere (D). Data are logarithmic ratios of fold inductions after MCAO 
vs. sham surgery (A,B) and VEGF vs. vehicle treatment (C,D). Data were analysed by two-
way ANOVA. *P< 0.05 compared with vehicle-treated ischemic mice. 
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4.13. VEGF-induced angiogenesis and axonal plasticity involves 
differential responses of growth inhibitory proteoglycans and 
guidance molecules in both hemispheres 
 
To clarify why VEGF influences angiogenesis and axonal plasticity in the two 
hemispheres in different ways, Western blots for the axonal growth inhibitory 
proteoglycans NG2 and brevican and for the vascular and axonal guidance proteins 
ephrin B1 and ephrin B2 were analyzed using tissue samples obtained from the 
ipsilesional and contralesional striatum. 
 
 In general, the abundance of these four proteins was upregulated in the 
subacute phase compared with acute phase of the stroke, particularly at 14 and 30 
dpi (Fig. 22). Intriguingly, VEGF administration did not influence the expression of 
these proteins in the ipsilesional striatum, which is traversed by descending 
pyramidal tract axons, but reduced the abundance of NG2, brevican and ephrin B2 in 
the contralesional striatum at 14 dpi (Fig. 22). Gene expression studies by RT-PCR 
revealed that VEGF downregulated the mRNAs of the proteoglycan neurocan (ncan), 
the guidance molecules ephrin B1 (eph B1) and netrin 1 (ntn1), and the neural cell 
adhesion molecule (ncam) in both hemispheres (Fig. 23). These data indicate that 
the fine-tuned regulation of new vessel formation and axonal growth takes place on 
the protein and not on the mRNA level. 
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Figure 22. VEGF downregulates growth inhibitory proteoglycans and guidance 
molecules in the contralesional hemisphere.  
Western blot analysis using antibodies detecting total NG2 proteoglycan (A, B), brevican (C, 
D), ephrin B1 (E, F) and ephrin B2 (G, H), both for the ipsilesional and contralesional 
striatum. Note the downregulation of the proteoglycans and guidance molecules in the 
contralesional non-ischemic striatum at 14 dpi. Data were normalized with values determined 
in the contralateral striatum of animals submitted to focal cerebral ischemia followed by 3 
days reperfusion. Protein loading was controlled with a β-actin antibody. Representative blots 
are shown. Data are means ± SD (n=3 Western blots). Data were analyzed by two-way 
ANOVA followed by two-tailed t-tests. *p< 0.05/ **p< 0.01 compared with non-ischemic 
vehicle. 
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Figure 23. The effect of VEGF on plasticity gene expression ipsi- and contralateral to 
stroke. 
 
Semi-quantitative RT-PCR analysis. Throughout the time period examined, focal cerebral 
ischemia did not modified the expression of ephB1, ncan, ntn1, ncam through time and 
regions after ischemia. 
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5. DISCUSSION 
 
5.1. General aspects regarding post-acute therapy with Epo and 
VEGF after stroke 
 
Using a comprehensive analysis of (i) motor and coordination deficits, (ii) 
reorganization processes of the peri-ischemic tissue, and (iii) pyramidal tract plasticity 
both ipsilateral and contralateral to the stroke, we found that post-acute delivery of 
the growth factors Epo and VEGF, initiated up to 72 hours after focal cerebral 
ischemia, promoted functional neurological recovery in mice submitted to transient 
intraluminal MCAO. Functional recovery was mediated by mechanisms involving 
perilesional tissue remodeling and promotion of contralateral pyramidal tract 
plasticity.  
 
An overlooked aspect regarding stroke therapy until now was the acceptance 
of the strong self-recovery post stroke phase that takes place physiologically after 
stroke and lasts for up to 72 hours. Trying to treat the injury within this phase by the 
means of different neuroprotective therapies proved to be ineffective in the clinic, one 
of the explanations being the possible interference with the innate recovery capacity 
of the brain. This self-recovery phase was the subject of many intensive studies in 
preclinical research, leading to the conclusion that stroke reactivates the dormant 
ontogenetic program in the brain (Cramer and Chopp, 2000). This reactivation takes 
place on different levels, from new activation of genetic programmes, new synthesis 
of proteins, and new production of cells: neurogenesis (Li and Chopp, 1999), 
angiogenesis (Li et al., 1997), synaptogenesis (Albensi, 2001) up to macroscopic 
restructuration of anatomical pathways and cortical remapping (Dancause et al., 
2005; Dijkhuizen et al., 2003). 
 
In the present studies, growth factors were administered via miniosmotic 
pumps starting 3 dpi after stroke until 30 dpi. Our main outcome parameters were 
functional recovery after stroke, together with anatomical modulation of axonal 
regeneration due to tract-tracing studies.  
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Both Epo and VEGF promote neurological recovery beyond the acute stroke 
phase, opening new perspectives for post-acute therapies. In contrast to acute 
neuroprotection, which aims at preserving ischemic neurons from apoptotic or 
necrotic injury and which has so far proven impossible beyond a time-window of 3 to 
6 hours after the stroke (Minnerup et al., 2009), post-acute therapies aim at the 
reorganization of the brain, both in the vicinity of the stroke lesion (Cramer and 
Chopp, 2000) and in remote areas (Wiessner et al., 2003). Slowly progressing 
secondary degeneration takes place in the striatum of vehicle-treated mice submitted 
to transient intraluminal MCAO, reflected by a continued loss of neurons and 
secondary tissue shrinkage, which in our study were both reduced by Epo and 
VEGF. The possibility that secondary neurodegeneration in the vicinity of the lesion 
may be relevant for stroke recovery has also been proposed by Taguchi et al. (2007), 
who reported deterioration of neurological deficits due to enhanced brain atrophy in 
granulocyte-colony stimulating factor (G-CSF)-treated mice submitted to distal 
MCAO.  
 
Besides preventing delayed neurodegeneration, Epo and VEGF induced 
angiogenesis and inhibited reactive astrogliosis, at the same time preventing scar 
formation of ischemic tissue. Our data are in agreement with studies by Li et al. 
(2009), who made MRI-based observation of peri-lesional white matter remodeling in 
MCAO rats treated with Epo within 24 hours of reperfusion. Inhibition of glial scar 
formation was reported in studies evaluating cell based therapies, namely bone 
marrow-derived stem cells (Li et al., 2005) and adult neural precursor cells 
(Bacigaluppi et al., 2009), indicating that Epo and VEGF share common mechanisms 
of action with these cells. In contrast to Epo and VEGF, adult neural stem/ precursor 
cells did not stimulate angiogenesis (Bacigaluppi et al., 2009). An advantage of Epo 
as compared to cell-based therapies, namely with neural precursor cells, is the lack 
of malignant tumor growth, which still remains a risk for the latter that cannot entirely 
be ruled out (Amariglio et al., 2009). 
The interhemispheric interaction after stroke is misbalanced; many pre-clinical 
and clinical studies reported an inhibition of the ipsilesional hemisphere by the 
contralesional hemisphere, inhibition that might be useful for improving cortical output 
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(Nair et al., 2007). It was also reported that after stroke the bilateral motor control 
from childhood is reactivated, meaning that the contralesional corticospinal tract may 
take over functional innervation of the hemiplegic body region (Nelles et al., 1999).  
Schwab and his co-authors successfully established anterograde neuronal tract 
tracing of the contralesional corticospinal tract as a tool for proving neuronal plasticity 
after stroke (Papadopoulus et al., 2002; Seymour et al., 2005). In our study we go a 
step further by applying an anterograde tract tracer in the ipsilesional motor cortex in 
addition to the contralesional one, which enables analysis of the impact of high dose 
Epo therapy on bilateral corticospinal tracts after stroke injury. 
 
In the present studies, induction of focal cerebral ischemia significantly 
increased axonal plasticity ipsilateral to the stroke, namely at the level of the facial 
nucleus. Remodelling of the pyramidal tract investigated by means of manganese-
enhanced MRI in rats from 4-10 weeks after 90 min MCAO showed significantly 
increased manganese transport in contralesional brain structures after ipsilesional 
motor cortex injections, suggesting enhanced interhemispheric axonal growth (van 
der Zijden et al., 2008). Unlike dextran amines, manganese is a combined 
anterograde (Canals et al., 2008) and retrograde (Matsuda et al., 2010) tracer, which 
is transsynaptically transported. Histochemical studies showed that focal cerebral 
ischemia induces the growth of short distance fibres (Carmichael et al., 2001) and 
promotes dendritic spine formation (Brown et al., 2007) in the perilesional tissue 
ipsilateral to the stroke, proving a short distance remodeling after stroke. The present 
data confirm once again that plasticity is indeed induced after stroke and that it not 
only affects short distance but also long distance projections.  
 
In view of the enhanced plasticity ipsilateral to the stroke, which we observed 
in vehicle-treated ischemic mice, it is noteworthy that Epo and VEGF did not further 
enhance ipsilesional pyramidal tract plasticity but rather showed a tendency to 
reduce it (p=0.07 at the level of the facial nucleus for Epo and p>0.1 for VEGF). 
Instead, both growth factors significantly increased the projections from the 
contralesional motor cortex towards the denervated red and facial nuclei. 
Contralesional sprouting was shown to correlate with functional neurological recovery 
after antagonization of the neurite growth inhibitor NogoA (Papadopoulos et al., 
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2002; Wiessner et al., 2003) and bone marrow-derived stem cell therapy (Andrews et 
al., 2008). In case of neutralizing NogoA antibodies, close correlations between the 
degree of functional neurological recovery and contralateral sprouting have been 
reported (Papadoupolus et al., 2002; Wiessner et al., 2003), demonstrating that 
cerebral connectivity represents a useful marker for the recovery processes. The 
present data confirm that stroke induces plasticity in the lesioned hemisphere and 
that Epo and VEGF shift plasticity towards the contralesional hemisphere, with a 
beneficial effect on functional recovery.  
 
5.2. Specific aspects regarding Epo therapy after stroke 
 
In the present study, Epo exhibited pronounced anti-inflammatory actions, 
which coincided with a reduction of leukocyte infiltration that persisted as long as Epo 
was infused. It has already been shown that Epo and its non-erythropoietic 
derivatives exhibit anti-inflammatory actions when delivered in the acute stroke 
phase. The resulting reduced leukocyte infiltration (Villa et al., 2003, 2007) 
decreased release of TNF-α, IL-6 and monocyte chemoattractant protein-1 (Villa et 
al., 2003) and diminished expression of iNOS (Kilic et al., 2005a). In cell culture, 
astrocytes but not leukocytes were shown to be responsive to Epo administration 
(Villa et al., 2003), suggesting that reduced release of inflammatory signals may be 
the trigger for the reduced invasion of blood-borne cells into the brain.  
 
By means of RT-PCR we revealed that Epo downregulated the pro-
inflammatory genes for IL-1β, TNF-α, LIF, TGF-β, IL-6, GFAP and iNOS, indicating 
that anti-inflammation may represent a mode of action, via which Epo enables brain 
reorganisation. Interestingly, pump removal in our study resulted in a rebound of 
leukocyte infiltration in Epo-treated mice, which however did not result in the 
reemergence of neurological deficits. Our data argue in favour of a critical time 
window, in which inflammatory responses impair recovery processes in the ischemic 
brain. 
 
In addition, RT-PCR-based profiling of pro-plasticity genes showed that Epo 
diminished the expression of the pro-plasticity mRNAs SPRR1, IGF-1 and KDR in the 
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ischemic hemisphere, which were increased by the stroke. At the same time, Epo 
downregulated the anti-plasticity mRNAs neurocan and ephrin B1 and upregulated 
the pro-plasticity SPRR1 in the non-ischemic hemisphere. In case of SPRR1A, 
downregulation was also demonstrated on the protein level by means of Western 
blots. Upregulation of pro-plasticity markers in the lesion border zone has previously 
been described after permanent cortical ischemia for SPRR1, MARCKS, GAP 43 and 
synaptophysin, as well as delayed upregulation of anti-plasticity markers for 
neurocan and ephrin B1 (Carmichael and Li, 2006; Stroemer et al., 1995).  
 
In our study, Epo regulated several pro- and anti-plasticity genes, especially in 
the non-ischemic hemisphere at 30 days post stroke, thus providing evidence for a 
specific plasticity modulating action of this growth factor. This is in accordance with 
previous studies on plasticity-promoting actions of Epo in rodent models of 
Parkinson’s disease (McLeod et al., 2006) and following optic nerve transaction (King 
et al., 2007). The present study shows that Epo's plasticity effects are relevant for the 
stroke recovery processes. 
 
After the German multicenter Epo trial, which recently showed unfavourable 
effects of Epo in patients undergoing thrombolysis (Ehrenreich et al., 2009), 
presumably due to exacerbation of extracellular matrix degradation by combined 
tissue-plasminogen activator / Epo treatment (Zechariah et al., 2010), further 
neuroprotection studies with Epo in the acute stroke phase are rather unlikely. Our 
present study offers a basis for the prolongation of time windows far into the sub-
acute stroke phase, thus paving the way for plasticity-promoting trials with Epo, its 
non-erythropoietic derivatives (Leist et al., 2004) or with small molecule agonists of 
Epo receptors (Pankratova et al., 2010). The latter compounds, for which the utility 
for systemic delivery still has to be shown, may be specifically tailored to bind to 
Epo’s CNS receptors. Non-erythropoietic derivatives of Epo do not induce 
hematoglobin or coagulation changes, and thus do not bear an elevated risk of 
thrombembolic events, which has recently been discussed in the context of chronic 
kidney disease trials (Pfeffer et al., 2009). With these considerations, proof-of-
concept studies in human patients have interesting potential.  
 
89 
 
5.3. Specific aspects regarding VEGF therapy after stroke 
 
 Despite the fact that we used a delayed delivery protocol, with VEGF applied 
starting only 72 hours after the stroke, VEGF potently induced neuronal survival in 
the ischemic striatum, which accompanied the enhanced angiogenesis in the 
perilesional tissue. VEGF protected the brain against delayed neuronal death, 
inhibiting caspase-3-dependent apoptotic injury, and thus preventing post-acute 
tissue shrinkage. This observation highlights the importance of preventing 
degenerative processes in the ischemic brain, which continue to progress over up to 
two to six weeks (Bacigaluppi et al., 2009; Reitmeir et al., 2011; 2012). Perilesional 
angiogenesis and neuroprotection have repeatedly been described after acute VEGF 
delivery (Zhang et al., 2000; Sun et al., 2003; Wang et al., 2005). The 
neuroprotective effect of VEGF involves the release of neurotrophic growth factors 
from cerebral microvascular cells (Zhang and Chopp, 2009) as well as direct 
neurotrophic effects of VEGF (Wick et al., 2002; Kilic et al., 2006). 
 
 Because VEGF promoted angiogenesis and neuronal survival, the question 
arose whether this enhanced neurovascular remodeling is accompanied by long 
distance axonal plasticity. Congrous responses of vessels and axons to VEGF 
exposure could be expected based on observations during ontogeny, where 
angiogenesis and neuronal sprouting are closely linked. Throughout the periphery of 
the body, blood vessels and peripheral nerves share nerve and vessel sheaths, and 
navigate by very similar and partly overlapping growth and guidance cues (Giger et 
al., 2010). Examples are members of the slit and semaphorin families that are 
involved in blood vessel and nerve guidance (Autiero et al., 2005). Because 
angiogenesis and axonal sprouting are not jointly regulated after stroke, like 
angiogenesis and neuronal survival, but are instead spatially segregated from each 
other indicates that the responses of the adult CNS to injury differs from peripheral 
nerve-vessel systems. 
 
In the induction of post-ischemic angiogenesis, MMPs, namely MMP9, plays a 
crucial role. MMP9 contributes to the breakdown of the ECM, which prepares the 
stage for vascular growth. Following acute VEGF delivery, MMP9 activity increases in 
90 
 
the perilesional ischemic tissue, closely in line with leaky vessels that are formed 
(Valable et al., 2005). The brain response to chronic VEGF differs from acute VEGF 
delivery, as shown in this report, since MMP9 was inhibited instead of activated by 
the growth factor. The downregulation of VEGF may reflect the maturation of newly 
formed brain vessels. MMP9 has not only been involved in angiogenesis, but also in 
axonal remodeling and repair. By cleaving growth inhibitory proteins, such as the 
proteoglycan NG2, MMP9 was suggested to contribute to axonal myelination 
processes. Impaired remyelination was observed in mice lacking MMP9 after 
lysolecithin-induced demyelination, which was interpreted as a consequence of the 
lack of proteoglycan proteolysis (Larsen et al., 2003). 
 
 In the ischemic brain, a link between MMP9 and neurovascular remodeling 
was shown by Zhao et al. (2006), who reported delayed expression of MMPs in peri-
lesional cortex in brain areas exhibiting enhanced activation signals by means of 
functional MRI. Inhibition of MMP abolished this response, and it was concluded that 
MMP9 promotes both vascular remodeling and brain plasticity (Zhao et al., 2006). 
MMPs cleave the proteoglycan NG2, which plays an important role as inhibitor of 
oligodendrocyte maturation, and cleave proteins and glycoproteins acting as axonal 
growth inhibitors, namely NogoA and myelin-associated glycoprotein (Yong, 2005). In 
the present study VEGF selectively downregulated the proteoglycans NG2 and 
brevican in the contralesional, but not ipsilesional brain tissue, which may in part 
reflect a consequence of the deactivation of MMP9 in the ischemic hemisphere. The 
differential regulation of axonal growth inhibitors was noticed on the protein level, but 
not mRNA level, suggesting that the abundance of growth inhibitors following stroke 
may be controlled by degradation rather than de novo expression processes. 
 
 Clues for the spatial dissociation of angiogenesis and axonal plasticity may be 
derived not only from responses of axonal growth inhibitors, but also from the 
guidance molecules ephrin B1 and ephrin B2, which were, similar to NG2 and 
brevican, differentially regulated by VEGF in both hemispheres. Ephrins, namely 
ephrin B2, are required for developmental as well as tumor-associated angiogenesis, 
promoting the cellular internalization of VEGF receptors, namely of VEGF receptor-2 
that mediates angiogenesis (Sawamiphak et al., 2010; Wang et al., 2010). 
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Internalization of VEGFR2 is necessary for activation and downstream signaling of 
the receptor and is needed for the VEGF-induced extension of the cells, which sets 
the stage for vessel sprouting (Sawamiphak et al., 2010). Intriguingly, the effects of 
ephrins on axons differ from those on vessels. During development, ephrins may 
have attractant and repellent properties, depending on their site of action and the 
coexpression of ephrin receptors (Hindges et al., 2002). In contrast, in the adult brain, 
the primary role of ephrins in regeneration is repulsion (Giger et al., 2010). Ephrins 
are expressed on reactive astrocytes, namely on scar tissue (ephrin B2), and myelin 
(ephrin B1) following CNS injury (Fabes et al., 2007). Inhibition of EphA4, using a 
peptide antagonist or genetic deletion, increases the sprouting of corticospinal axons 
in vivo (Fabes et al., 2007) and promotes the outgrowth of neurites from cultured 
neurons (Goldshmit et al., 2004). From this perspective, the differential regulation of 
ephrin B2 and ephrin B1, i.e., their downregulation contralateral but not ipsilateral to 
the stroke, may have created a favorable environment in which pyramidal tract 
plasticity became possible. 
 
Our data show a dissociation of VEGF-induced angiogenesis and axonal 
plasticity between the ipsilesional and contralesional hemispheres that accompanies 
neurological recovery. This dissociation could be attributed to differential responses 
of extracellular matrix and guidance molecules in both hemispheres. 
 
6. CONCLUSIONS 
 
 The differential regulation of matrix proteinases, axonal growth inhibitors and 
guidance molecules opens fascinating perspectives for translational studies and for 
delineating targets via which the efficacy of therapeutics might be predicted. This 
provides opportunities for the development of neurorestorative therapies. However, 
our understanding of successful stroke recovery is still evolving. With a proper 
understanding of the mechanisms that guide new vessel formation and axonal 
plasticity, clinical proof-of-principle concept studies may show promising results.  
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